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Summary
Background Traumatic brain injury (TBI) and spinal cord injury (SCI) are increasingly recognised as global health 
priorities in view of the preventability of most injuries and the complex and expensive medical care they necessitate. We 
aimed to measure the incidence, prevalence, and years of life lived with disability (YLDs) for TBI and SCI from all causes 
of injury in every country, to describe how these measures have changed between 1990 and 2016, and to estimate the 
proportion of TBI and SCI cases caused by different types of injury.
Methods We used results from the Global Burden of Diseases, Injuries, and Risk Factors (GBD) Study 2016 to measure 
the global, regional, and national burden of TBI and SCI by age and sex. We measured the incidence and prevalence of 
all causes of injury requiring medical care in inpatient and outpatient records, literature studies, and survey data. By use 
of clinical record data, we estimated the proportion of each cause of injury that required medical care that would result in 
TBI or SCI being considered as the nature of injury. We used literature studies to establish standardised mortality ratios 
and applied differential equations to convert incidence to prevalence of long-term disability. Finally, we applied GBD 
disability weights to calculate YLDs. We used a Bayesian meta-regression tool for epidemiological modelling, used cause-
specific mortality rates for non-fatal estimation, and adjusted our results for disability experienced with comorbid 
conditions. We also analysed results on the basis of the Socio-demographic Index, a compound measure of income per 
capita, education, and fertility.
Findings In 2016, there were 27·08 million (95% uncertainty interval [UI] 24·30–30·30 million) new cases of TBI and 
0·93 million (0·78–1·16 million) new cases of SCI, with age-standardised incidence rates of 369 (331–412) per 
100 000 population for TBI and 13 (11–16) per 100 000 for SCI. In 2016, the number of prevalent cases of TBI was 
55·50 million (53·40–57·62 million) and of SCI was 27·04 million (24·98–30·15 million). From 1990 to 2016, the age-
standardised prevalence of TBI increased by 8·4% (95% UI 7·7 to 9·2), whereas that of SCI did not change significantly 
(–0·2% [–2·1 to 2·7]). Age-standardised incidence rates increased by 3·6% (1·8 to 5·5) for TBI, but did not change 
significantly for SCI (–3·6% [–7·4 to 4·0]). TBI caused 8·1 million (95% UI 6·0–10·4 million) YLDs and SCI caused 
9·5 million (6·7–12·4 million) YLDs in 2016, corresponding to age-standardised rates of 111 (82–141) per 100 000 for TBI 
and 130 (90–170) per 100 000 for SCI. Falls and road injuries were the leading causes of new cases of TBI and SCI in most 
regions.
Interpretation TBI and SCI constitute a considerable portion of the global injury burden and are caused primarily by 
falls and road injuries. The increase in incidence of TBI over time might continue in view of increases in population 
density, population ageing, and increasing use of motor vehicles, motorcycles, and bicycles. The number of individuals 
living with SCI is expected to increase in view of population growth, which is concerning because of the specialised care 
that people with SCI can require. Our study was limited by data sparsity in some regions, and it will be important to 
invest greater resources in collection of data for TBI and SCI to improve the accuracy of future assessments.
Funding Bill & Melinda Gates Foundation.
Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction
Traumatic brain injury (TBI) and spinal cord injury (SCI) 
are increasingly considered to be important global health 
priorities.1 These injuries not only cause health loss and 
disability for individ uals and their families, but also 
represent a burden to health-care systems and economies 
through lost pro ductivity and high health-care costs.2 
Given that the injuries that lead to TBI and SCI are 
frequently preventable, there is also value in measuring 
the extent to which different causes of injury lead to TBI 
or SCI to help to understand the effect that injury-
prevention programmes could have.
Many epidemiological studies have been limited by 
difficulties in comprehensively measuring the incidence 
of cross-injury sequelae such as TBI and SCI, and have 
instead focused on the incidence of the causes of injury, 
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such as falls, road injuries, and interpersonal violence.3 As 
a result, few comprehensive epidemi ological assessments 
have been done across all sources of injury, despite 
increasing dialogue about the long-term neuropsych-
ological consequences of con cussions in young people and 
professional athletes playing sports and about the risk of 
TBI from head trauma in bicycle crashes and other causes 
of injury.4,5 Epidemiological studies that have focused 
specifically on TBI and SCI without estimation of all 
potential causes of injury have identified substantial 
burdens, but are often limited by relying on locations 
where incidence data were available without adopting 
modelling strategies for estimation of the burden in 
locations where data were sparse.6–12 Epidemiological 
assessments have been done in low-income and low-
middle-income countries but typically have been limited 
by poor availability of data.7,12,13 Few studies have reported 
age-standardised incidence rates, which would enable 
comparison between countries with different popula tions, 
and the studies that have reported such data showed that 
the incidence rates of TBI and SCI vary substantially 
between countries.7,12 These studies have not measured the 
relative disability caused by different injuries over time; 
such data are important because, whereas injuries such as 
fractures might be disabling only in the short term, 
conditions such as cognitive impairment from TBI or 
paraplegia from SCI can leave patients with lifelong health 
loss. In general, measurement of the burden of TBI and 
SCI in greater geographical and demographic detail—and 
over time—is of substantial value.
The Global Burden of Diseases, Injuries, and Risk 
Factors (GBD) study is the product of a global research 
Research in context
Evidence before this study
Previous epidemiological studies of the incidence and 
outcomes of traumatic brain injury (TBI) and spinal cord injury 
(SCI) have been limited by focusing on certain subpopulations, 
including only select injuries, or by providing estimates only for 
areas of the world with accessible data. Previous Global Burden 
of Diseases, Injuries, and Risk Factors (GBD) studies have 
reported the burden of injury by cause of injury, such as 
self-harm, road injuries, and falls, but have not reported results 
by nature of injury sustained as a result of those causes, 
including TBI and SCI. To date, no studies have systematically 
measured the burden of TBI and SCI globally for all countries, 
ages, and sexes through recent years and from all causes of 
injury. To identify sources of injury data that could inform an 
assessment of non-fatal burden from TBI and SCI, we used 
results from the GBD 2016 injuries estimation process, which 
included systematic reviews of injury incidence data for all 
causes of injury that were initially done for GBD 2010 and 
updated as new data and literature studies became available in 
GBD 2013, GBD 2015, and GBD 2016. Inclusion criteria for the 
systematic reviews were representative, population-based 
surveys; reporting of injuries incidence; and clinical records 
from general hospitals, outpatient primary care facilities, and 
health insurance claims when such data were available with 
injury diagnosis codes. In this study, we updated a previous 
review of injuries data done for the World Bank that 
contributed to GBD 2010, GBD 2013, and GBD 2015 by 
searching the Global Health Data Exchange for surveys, hospital 
datasets, and literature studies in any language that were 
tagged as having injury-related data up to Dec 31, 2016.
Added value of this study
In this study, we used for the first time the GBD 2016 
framework to report estimates of the global, regional, and 
national burden in terms of incidence, prevalence, and years of 
life lived with disability of TBI and SCI for 195 countries and 
territories. We have provided these estimates globally, 
by region, and by Socio-demographic Index quintiles in 2016, 
as well as the percentage change since 1990. We also provide 
estimates of the proportions of TBI and SCI caused by different 
causes of injury for each geographical region in 2016. 
Although epidemiological assessments that focus on particular 
populations have been done, no other studies of TBI or SCI 
have provided estimates in this level of detail for all countries 
derived from a standardised, systematic approach. We were 
able to measure uncertainty in our estimates by using the 
uncertainty propogation methods used throughout the 
GBD study.
Implications of all the available evidence
Our estimates suggest that TBI and SCI are severely disabling 
injuries. The global burden of TBI increased significantly 
between 1990 and 2016, whereas that of SCI has not changed 
significantly over time in terms of age-standardised incidence 
and prevalence. Age-standardised incidence and prevalence of 
TBI and SCI were high in central Europe, eastern Europe, and 
central Asia; the incidence and prevalence of SCI were high in 
North America and western Europe. Addressing the global 
burden of these conditions requires improved efforts to 
decrease the causes of SCI and TBI (eg, fall-prevention 
strategies, reducing alcohol overuse, and improving road safety, 
all of which could help to prevent injuries or decrease injury 
severity) and improved access to, and quality of, medical and 
social care (which could improve survival and reduce 
morbidity). People with TBI or SCI can have other medical 
conditions that require close supervision and might benefit 
from rehabilitation and medical care to reduce disability. Hence, 
although injury prevention efforts are key, health-care systems 
should also anticipate a growing burden from caring for people 
with TBI and SCI. These conditions could necessitate special 
focus within health-care systems, because they can be medically 
complex and burdensome for patients, clinicians, and families. 
In the future, development of improved methods for 
surveillance of TBI and SCI will be important, particularly in 
low-income settings, as will development of methods to 
identify patients with TBI who do not seek medical care.
For the Global Health Data 
Exchange see http://ghdx.
healthdata.org
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Incidence Prevalence
2016 counts 2016 age-standardised 
rates (per 100 000)
Percentage change in 
age-standardised 
rates, 1990–2016
2016 counts 2016 age-standardised 
rates (per 100 000)
Percentage change in 
age-standardised rates, 
1990–2016
Global 27 082 033 
(24 302 091 to 
30 298 710)
369 
(331 to 412)
3·6 
(1·8 to 5·5)
55 495 674 
(53 400 547 to 
57 626 214)
759 
(731 to 788)
8·4 
(7·7 to 9·2)
High SDI 3 682 268 
(3 112 645 to 4 394 060)
343 
(293 to 403)
–9·4 
(–12·2 to –6·2)
8 463 137 
(8 121 296 to 8 818 355)
647 (619 to 675) –7·9 (–8·7 to –7·1)
High-middle SDI 5 550 132 
(4 977 125 to 6 205 225)
468 
(419 to 523)
–10·7 
(–13·3 to –8·4)
13 458 443 
(12 951 567 to 
13 973 353)
1032 
(993 to 1 074)
–5·4 
(–6·3 to –4·5)
Middle SDI 7 279 905 
(6 580 600 to 8 046 104)
318 
(287 to 351)
21·8 
(18·8 to 24·9)
16 745 178 
(16 127 494 to 
17 364 295)
699 
(674 to 725)
32·4 
(31·0 to 33·9)
Low-middle SDI 8 074 189 
(7 244 954 to 8 969 510)
397 
(356 to 441)
11·1 
(7·6 to 16·5)
13 524 272 
(12 971 769 to 
14 124 365)
747 
(717 to 778)
18·7 
(17·7 to 20·0)
Low SDI 2 607 230 
(2 291 622 to 2 997 764)
366 
(323 to 416)
–9·3 
(–14·7 to –6·0)
3 506 690 
(3 308 885 to 
3 760 344)
669 
(633 to 719)
3·3 
(1·9 to 4·8)
High income 3 274 760 
(2 736 209 to 3 975 372)
298 
(251 to 354)
–9·6 
(–13·0 to –6·1)
7 330 041 
(7 013 363 to 
7 655 518)
544 
(520 to 569)
–10·2 
(–11·0 to –9·2)
High-income North 
America
1 221 494 
(1 019 814 to 1 475 250)
329 
(277 to 392)
–4·1 
(–8·8 to 1·2)
2 603 351 
(2 488 042 to 
2 726 560)
600 
(573 to 630)
–6·3 
(–7·9 to –4·6)
Canada 110 332 
(92 166 to 133 581)
302 
(254 to 361)
–10·4 
(–15·2 to –6·0)
253 144 
(241 660 to 265 695)
558 
(532 to 586)
–11·2 
(–12·9 to –9·2)
Greenland 161 
(133 to 197)
321 
(267 to 389)
–19·0 
(–21·3 to –16·5)
281 
(269 to 296)
525 
(502 to 553)
–14·6 
(–15·9 to –13·2)
USA 1 110 578 
(927 814 to 1 340 515)
333 
(280 to 396)
–3·3 
(–8·2 to 2·5)
2 349 017 
(2 244 955 to 2 461 041)
605 
(577 to 635)
–5·7 
(–7·5 to –3·9)
Australasia 78 554 
(65 710 to 93 741)
276 
(231 to 327)
–13·0 
(–18·6 to –7·3)
178 663 
(170 767 to 187 588)
528 
(503 to 556)
–14·1 
(–15·6 to –12·2)
Australia 66 020 
(55 309 to 78 895)
275 
(230 to 327)
–12·1 
(–17·8 to –6·3)
150 213 
(143 534 to 157 799)
527 
(503 to 555)
–13·3 
(–14·9 to –11·3)
New Zealand 12 535 
(10 560 to 14 974)
279 
(236 to 330)
–17·1 
(–23·2 to –11·1)
28 450 
(27 152 to 29 828)
534 
(508 to 561)
–18·1 
(–20·3 to –16·1)
High-income Asia Pacific 563 538 
(471 687 to 681 672)
276 
(231 to 330)
–16·9 
(–20·6 to –13·1)
1 256 353 
(1 203 704 to 1 308 375)
489 
(467 to 511)
–14·8 
(–16·1 to –13·5)
Brunei 1535 
(1306 to 1819)
384 
(325 to 456)
–20·7 
(–24·6 to –16·6)
2708 
(2564 to 2857)
673 
(640 to 708)
–21·3 
(–22·7 to –19·9)
Japan 382 954 
(317 505 to 467 002)
263 
(220 to 314)
–15·5 
(–19·9 to –11·2)
891 110 
(854 680 to 928 073)
474 
(452 to 496)
–14·2 
(–15·8 to –12·4)
Singapore 11 193 
(9348 to 13 379)
285 
(238 to 340)
–4·4 
(–10·0 to 0·6)
24 309 
(23 165 to 25 421)
516 
(491 to 540)
–0·8 
(–3·0 to 1·5)
South Korea 167 856 
(141 874 to 199 972)
316 
(267 to 377)
–19·4 
(–23·8 to –14·7)
338 225 
(323 467 to 352 938)
535 
(510 to 559)
–18·4 
(–20·1 to –17·0)
Western Europe 1 262 700 
(1 042 418 to 1 546 907)
292 
(244 to 351)
–13·4 
(–17·2 to –9·7)
3 021 435 
(2 880 245 to 3 154 517)
546 
(519 to 572)
–12·8 
(–13·8 to –11·7)
Andorra 236 
(194 to 292)
300 
(249 to 361)
4·1 
(0·8 to 7·5)
583 
(554 to 611)
565 
(536 to 594)
6·2 
(4·7 to 7·7)
Austria 28 255 
(23 166 to 35 170)
322 
(266 to 388)
–19·9 
(–24·5 to –14·8)
66 670 
(63 606 to 69 564)
589 
(561 to 616)
–17·7 
(–19·4 to –16·2)
Belgium 41 126 
(33 848 to 51 024)
344 
(287 to 416)
–6·8 
(–13·6 to –0·6)
90 487 
(86 268 to 94 639)
621 
(590 to 652)
–10·1 
(–11·7 to –8·1)
Cyprus 2959 
(2503 to 3516)
323 
(273 to 381)
–10·0 
(–14·2 to –5·6)
6605 
(6280 to 6947)
618 
(588 to 650)
–9·0 
(–10·3 to –7·6)
Denmark 17 302 
(14 208 to 21 444)
301 
(249 to 366)
–14·9 
(–19·7 to –10·0)
39 756 
(37 914 to 41 590)
556 
(529 to 584)
–12·5 
(–14·0 to –11·0)
(Table 1 continues on next page)
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Incidence Prevalence
2016 counts 2016 age-standardised 
rates (per 100 000)
Percentage change in 
age-standardised 
rates, 1990–2016
2016 counts 2016 age-standardised 
rates (per 100 000)
Percentage change in 
age-standardised rates, 
1990–2016
(Continued from previous page)
Finland 20 009 
(16 226 to 25 470)
344 
(284 to 420)
–5·5 
(–10·4 to –0·8)
44 056 
(42 012 to 46 103)
609 
(579 to 637)
–4·5 
(–6·3 to –2·8)
France 209 986 
(170 948 to 261 143)
307 
(255 to 372)
–19·9 
(–24·6 to –15·3)
466 018 
(442 758 to 488 496)
564 
(535 to 593)
–19·8 
(–21·4 to –18·1)
Germany 236 043 
(192 862 to 295 657)
288 
(239 to 346)
–12·8 
(–18·4 to –7·7)
592 273 
(564 640 to 619 584)
535 
(508 to 562)
–12·6 
(–14·2 to –11·1)
Greece 33 094 
(27 874 to 39 411)
321 
(271 to 382)
–9·7 
(–14·8 to –4·8)
89 972 
(85 526 to 94 453)
627 
(594 to 660)
–7·9 
(–9·2 to –6·4)
Iceland 926 
(766 to 1120)
282 
(233 to 339)
–7·5 
(–11·9 to –2·8)
2021 
(1925 to 2110)
532 
(506 to 557)
–7·1 
(–8·8 to –5·3)
Ireland 13 298 
(10 956 to 16 111)
297 
(246 to 356)
–6·0 
(–11·1 to –0·6)
28 873 
(27 464 to 30 268)
550 
(523 to 578)
–6·5 
(–8·1 to –4·9)
Israel 22 803 
(18 980 to 27 302)
278 
(232 to 332)
–4·5 
(–11·5 to 1·3)
45 734 
(42 915 to 49 699)
556 
(521 to 605)
4·0 
(1·0 to 8·4)
Italy 191 527 
(158 858 to 231 854)
315 
(263 to 377)
–11·7 
(–15·7 to –7·3)
491 141 
(468 037 to 514 611)
596 
(566 to 626)
–10·2 
(–11·7 to –8·7)
Luxembourg 1771 
(1461 to 2157)
303 
(252 to 367)
–26·5 
(–31·5 to –21·9)
3980 
(3783 to 4168)
563 
(535 to 591)
–25·7 
(–27·1 to –24·3)
Malta 1170 
(965 to 1445)
289 
(240 to 352)
–8·9 
(–12·4 to –5·1)
2870 
(2741 to 3000)
539 
(514 to 566)
–5·7 
(–7·1 to –4·4)
Netherlands 46 656 
(38 792 to 56 158)
275 
(233 to 327)
0·0 
(–5·4 to 5·8)
112 886 
(107 893 to 118 007)
523 
(499 to 549)
1·2 
(–0·8 to 3·1)
Norway 15 956 
(13 059 to 19 836)
298 
(246 to 363)
–5·5 
(–10·5 to –0·9)
34 915 
(33 251 to 36 587)
547 
(519 to 574)
–4·3 
(–5·8 to –2·5)
Portugal 28 078 
(23 484 to 33 755)
267 
(226 to 316)
–29·3 
(–34·6 to –24·6)
70 982 
(67 792 to 74 142)
504 
(480 to 527)
–28·5 
(–30·3 to –26·6)
Spain 128 447 
(107 057 to 155 547)
284 
(237 to 339)
–16·4 
(–21·3 to –11·4)
328 217 
(312 784 to 343 173)
543 
(515 to 569)
–16·5 
(–18·0 to –14·6)
Sweden 28 106 
(22 808 to 34 819)
282 
(233 to 342)
–4·6 
(–9·1 to –0·1)
63 463 
(60 718 to 66 262)
512 
(488 to 536)
–5·9 
(–7·6 to –4·2)
Switzerland 25 123 
(20 227 to 31 494)  
284 
(233 to 343)
–29·1 
(–33·8 to –24·9)
54 812 
(52 351 to 57 096)
499 
(476 to 520)
–29·4 
(–30·9 to –27·9)
UK 168 579 
(137 783 to 208 313)
260 
(215 to 316)
–5·9 
(–9·9 to –2·0)
382 133 
(364 581 to 399 049)
478 
(454 to 499)
–6·5 
(–7·5 to –5·3)
Southern Latin America 148 473 
(124 980 to 179 016)
225 
(190 to 271)
11·7 
(8·7 to 14·8)
270 239 
(259 242 to 281 576)
392 
(376 to 409)
15·1 
(13·9 to 16·5)
Argentina 100 117 
(84 470 to 120 244)
228 
(192 to 273)
14·0 
(9·8 to 18·2)
179 575 
(172 271 to 187 296)
401 
(384 to 418)
18·0 
(16·4 to 19·7)
Chile 39 688 
(32 980 to 47 814)
214 
(178 to 257)
4·4 
(1·1 to 7·7)
74 082 
(71 084 to 77 306)
368 
(352 to 384)
8·0 
(6·3 to 9·5)
Uruguay 8662 
(7243 to 10 453)
244 
(205 to 294)
13·8 
(9·4 to 18·3)
16 567 
(15 878 to 17 280)
424 
(406 to 443)
17·0 
(15·2 to 19·0)
Central Europe, eastern 
Europe, and central Asia 
3 174 597 
(2 813 645 to 3 622 489)
740 
(657 to 844)
–4·2 
(–6·3 to –2·2)
7 505 017 
(7 139 954 to 
7 872 426)
1539 
(1464 to 1614)
–0·6 
(–1·5 to 0·6)
Eastern Europe 1 679 786 
(1 495 412 to 1 908 308)
772 
(688 to 876)
–2·4 
(–5·2 to 0·3)
3 987 022 
(3 796 684 to 4 175 331)
1546 
(1472 to 1623)
–1·5 
(–3·0 to 0·2)
Belarus 85 268 
(74 665 to 98 805)
853 
(749 to 979)
15·8 
(11·5 to 20·3)
203 206 
(192 572 to 213 647)
1724 
(1632 to 1815)
15·2 
(12·9 to 17·9)
Estonia 9843 
(8618 to 11 372)
722 
(635 to 827)
–20·2 
(–24·0 to –16·0)
25 698 
(24 398 to 27 131)
1529 
(1445 to 1622)
–14·1 
(–16·2 to –11·8)
Latvia 15 511 
(13 648 to 17 822)
743 
(654 to 851)
–22·6 
(–26·0 to –18·8)
38 996 
(37 015 to 40 989)
1519 
(1436 to 1601)
–18·4 
(–20·2 to –16·6)
Lithuania 26 381 
(23 106 to 30 541)
845 
(743 to 972)
–5·5 
(–9·4 to –1·3)
64 738 
(61 519 to 68 064)
1709 
(1618 to 1800)
–3·8 
(–5·7 to –1·9)
(Table 1 continues on next page)
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Incidence Prevalence
2016 counts 2016 age-standardised 
rates (per 100 000)
Percentage change in 
age-standardised 
rates, 1990–2016
2016 counts 2016 age-standardised 
rates (per 100 000)
Percentage change in 
age-standardised rates, 
1990–2016
(Continued from previous page)
Moldova 25 099 
(22 243 to 28 672)
609 
(537 to 696)
–17·6 
(–21·2 to –14·0)
58 867 
(55 632 to 62 363)
1251 
(1181 to 1327)
–14·2 
(–16·4 to –12·0)
Russia 1 202 502 
(1 074 273 to 1 364 131)
799 
(715 to 905)
–1·5 
(–4·9 to 2·2)
2 810 261 
(2 678 210 to 2 939 902)
1589 
(1512 to 1668)
–0·6 
(–2·5 to 1·6)
Ukraine 315 182 
(278 598 to 360 233)
683 
(605 to 779)
–6·5 
(–10·0 to –2·8)
785 255 
(745 321 to 824 796)
1390 
(1317 to 1464)
–6·1 
(–8·1 to –4·1)
Central Europe 1 055 830 
(916 104 to 1 233 304)
857 
(750 to 988)
–3·0 
(–5·9 to –0·4)
2 649 259 
(2 512 485 to 2 792 424)
1797 
(1699 to 1895)
4·4 
(3·3 to 5·5)
Albania 19 366 
(17 024 to 22 180)
662 
(583 to 761)
10·1 
(6·5 to 13·9)
48 963 
(46 227 to 51 786)
1490 
(1405 to 1577)
12·6 
(9·7 to 16·1)
Bosnia and Herzegovina 25 864 
(22 525 to 29 894)
688 
(599 to 793)
42·4 
(37·9 to 46·7)
76 617 
(71 724 to 82 170)
1600 
(1493 to 1714)
53·9 
(47·9 to 62·5)
Bulgaria 57 125 
(49 635 to 66 125)
776 
(683 to 897)
–5·3 
(–9·4 to –1·3)
157 661 
(149 402 to 165 850)
1663 
(1572 to 1756)
–1·8 
(–3·8 to 0·6)
Croatia 39 226 
(33 726 to 46 071)
801 
(704 to 914)
–3·1 
(–8·3 to 2·5)
92 177 
(87 994 to 96 575)
1627 
(1553 to 1703)
0·1 
(–2·8 to 3·3)
Czech Republic 115 120 
(98 857 to 135 307)
1022 
(885 to 1191)
–5·3 
(–9·8 to –0·3)
297 221 
(281 750 to 314 241)
2174 
(2051 to 2309)
9·1 
(6·7 to 11·5)
Hungary 96 761 
(82 027 to 115 438)
865 
(744 to 1018)
–19·0 
(–23·5 to –14·7)
221 514 
(209 001 to 234 108)
1707 
(1606 to 1810)
–8·8 
(–11·2 to –6·4)
Macedonia 14 795 
(12 858 to 17 014)
714 
(621 to 821)
16·0 
(11·9 to 20·0)
37 193 
(35 009 to 39 447)
1526 
(1434 to 1621)
18·3 
(15·2 to 21·3)
Montenegro 4976 
(4367 to 5690)
785 
(688 to 897)
8·5 
(5·3 to 11·7)
12 611 
(11 930 to 13 318)
1712 
(1615 to 1810)
11·5 
(9·3 to 13·9)
Poland 370 019 
(319 509 to 432 391)
893 
(782 to 1038)
1·0 
(–3·6 to 5·2)
908 548 
(860 062 to 960 247)
1856 
(1753 to 1964)
9·1 
(6·7 to 11·3)
Romania 169 215 
(146 358 to 196 891)
834 
(729 to 966)
–7·9 
(–12·5 to –3·4)
434 844 
(411 374 to 458 018)
1751 
(1653 to 1847)
–5·0 
(–6·9 to –3·1)
Serbia 65 967 
(57 683 to 75 848)
733 
(642 to 840)
13·4 
(10·0 to 16·7)
174 644 
(164 893 to 184 515)
1604 
(1511 to 1705)
17·9 
(14·9 to 21·6)
Slovakia 51 215 
(44 217 to 60 241)
889 
(775 to 1031)
–9·9 
(–13·3 to –6·0)
123 805 
(117 261 to 130 731)
1831 
(1730 to 1936)
–2·0 
(–3·9 to 0·4)
Slovenia 26 182 
(22 098 to 31 703)
1092 
(938 to 1294)
–3·8 
(–9·3 to 3·1)
63 460 
(60 084 to 67 002)
2255 
(2133 to 2384)
3·2 
(1·3 to 5·5)
Central Asia 438 981 
(389 647 to 498 547)
495 
(439 to 563)
0·1 
(–2·3 to 2·4)
868 736 
(823 691 to 916 878)
1054 
(1002 to 1109)
1·9 
(0·7 to 3·2)
Armenia 14 329 
(12 636 to 16 274)
474 
(417 to 539)
–12·4 
(–16·1 to –8·6)
39 865 
(36 019 to 45 144)
1171 
(1057 to 1325)
–13·3 
(–17·4 to –9·4)
Azerbaijan 45 533 
(40 390 to 51 890)
465 
(410 to 530)
–3·4 
(–6·9 to 0·1)
101 481 
(95 966 to 107 296)
1008 
(954 to 1065)
1·6 
(–0·9 to 4·5)
Georgia 20 209 
(17 948 to 22 994)
496 
(440 to 563)
–4·6 
(–8·2 to –1·3)
48 707 
(46 371 to 51 143)
1046 
(994 to 1100)
–3·0 
(–5·6 to –0·1)
Kazakhstan 108 784 
(96 745 to 122 858)
609 
(541 to 689)
9·8 
(5·7 to 14·2)
217 996 
(206 528 to 229 023)
1251 
(1187 to 1313)
11·3 
(8·8 to 13·9)
Kyrgyzstan 28 144 
(24 869 to 31 895)
470 
(417 to 532)
–13·1 
(–16·7 to –9·6)
51 346 
(48 550 to 54 313)
989 
(940 to 1043)
–9·6 
(–12·0 to –7·2)
Mongolia 19 388 
(17 259 to 22 037)
634 
(563 to 723)
51·3 
(43·5 to 58·0)
34 544 
(32 803 to 36 466)
1258 
(1197 to 1325)
52·1 
(47·4 to 56·6)
Tajikistan 35 891 
(31 281 to 41 437)
417 
(364 to 482)
–13·3 
(–16·9 to –9·8)
62 285 
(58 266 to 66 604)
918 
(861 to 978)
–6·9 
(–10·1 to –2·7)
Turkmenistan 24 881 
(22 055 to 28 455)
448 
(398 to 512)
–0·2 
(–3·7 to 3·6)
46 815 
(44 152 to 49 691)
945 
(894 to 999)
3·6 
(1·0 to 5·9)
Uzbekistan 141 821 
(125 591 to 160 782)
459 
(405 to 521)
4·0 
(0·1 to 7·5)
265 697 
(251 467 to 282 482)
963 
(913 to 1019)
5·4 
(3·0 to 7·9)
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Latin America and 
Caribbean
1 845 785 
(1 656 712 to 2 074 570)
330 
(296 to 372)
1·1 
(–0·9 to 3·3)
3 721 363 
(3 549 097 to 
3 887 453)
681 
(650 to 710)
3·6 
(2·2 to 4·9)
Central Latin America 716 600 
(642 948 to 806 959)
293 
(263 to 330)
–9·5 
(–11·6 to –7·6)
1 412 146 
(1 349 779 to 1 474 463)
609 
(584 to 635)
–5·0 
(–5·9 to –3·9)
Colombia 139 297 
(124 785 to 157 283)
294 
(263 to 331)
–8·7 
(–12·1 to –5·1)
300 952 
(287 367 to 315 562)
632 
(605 to 663)
–1·7 
(–4·0 to 0·3)
Costa Rica 15 073 
(13 458 to 17 031)
316 
(281 to 357)
18·3 
(13·8 to 23·1)
33 681 
(31 961 to 35 326)
677 
(643 to 710)
24·8 
(21·5 to 28·3)
El Salvador 19 120 
(16 989 to 21 613)
317 
(282 to 359)
1·0 
(–7·3 to 7·0)
37 724 
(35 524 to 40 291)
660 
(622 to 705)
5·5 
(–0·5 to 9·6)
Guatemala 45 833 
(40 822 to 51 724)
301 
(269 to 341)
14·2 
(6·5 to 19·9)
73 308 
(69 788 to 77 152)
593 
(568 to 620)
19·1 
(15·0 to 22·4)
Honduras 20 923 
(18 552 to 23 757)
279 
(246 to 317)
30·4 
(25·3 to 36·2)
37 596 
(34 937 to 40 813)
567 
(532 to 610)
33·1 
(26·4 to 42·1)
Mexico 341 669 
(306 552 to 384 904)
279 
(249 to 315)
–19·7 
(–21·8 to –17·7)
658 215 
(628 280 to 687 951)
565 
(540 to 589)
–16·9 
(–18·0 to –15·6)
Nicaragua 15 254 
(13 573 to 17 337)
263 
(233 to 299)
4·8 
(1·1 to 8·7)
29 229 
(27 333 to 31 642)
564 
(531 to 609)
–0·0 
(–5·3 to 4·5)
Panama 12 357 
(11 042 to 13 915)
315 
(281 to 354)
19·1 
(15·2 to 23·4)
25 833 
(24 514 to 27 043)
683 
(649 to 715)
24·0 
(20·8 to 27·1)
Venezuela 107 073 
(96 052 to 119 963)
348 
(313 to 390)
14·0 
(9·4 to 18·7)
215 609 
(205 565 to 225 532)
742 
(709 to 775)
19·6 
(16·8 to 22·5)
Andean Latin America 175 372 
(157 046 to 195 338)
303 
(271 to 340)
7·9 
(4·7 to 11·2)
338 065 
(320 850 to 354 351)
640 
(610 to 670)
12·1 
(10·2 to 14·0)
Bolivia 31 106 
(27 863 to 34 867)
294 
(262 to 329)
–4·0 
(–7·0 to –1·2)
55 875 
(53 030 to 58 747)
608 
(579 to 638)
2·6 
(0·2 to 5·1)
Ecuador 55 753 
(49 257 to 63 120)
350 
(310 to 398)
16·5 
(9·0 to 26·0)
101 553 
(96 588 to 106 302)
696 
(663 to 728)
11·8 
(9·3 to 14·3)
Peru 88 513 
(78 933 to 98 960)
282 
(252 to 316)
6·8 
(2·3 to 11·4)
180 637 
(170 825 to 189 957)
622 
(590 to 652)
15·1 
(11·8 to 18·3)
Caribbean 145 899 
(130 066 to 163 629)
320 
(285 to 360)
21·1 
(17·9 to 24·5)
322 291 
(292 210 to 359 914)
706 
(640 to 788)
29·9 
(20·2 to 44·6)
Antigua and Barbuda 263 
(235 to 295)
291 
(259 to 326)
15·4 
(12·3 to 18·8)
596 
(566 to 625)
640 
(607 to 671)
18·5 
(15·6 to 21·4)
The Bahamas 1222 
(1097 to 1368)
314 
(281 to 352)
6·3 
(2·9 to 9·8)
2720 
(2591 to 2843)
660 
(629 to 690)
11·2 
(8·6 to 14·5)
Barbados 782 
(697 to 875)
275 
(246 to 309)
19·2 
(16·2 to 22·5)
1995 
(1899 to 2084)
600 
(569 to 628)
23·1 
(19·9 to 26·3)
Belize 1148 
(1029 to 1282)
321 
(289 to 358)
32·3 
(26·4 to 37·1)
1969 
(1873 to 2056)
659 
(629 to 685)
31·7 
(28·6 to 35·3)
Bermuda 226 
(201 to 253)
322 
(286 to 361)
–4·0 
(–7·5 to –0·2)
515 
(490 to 539)
719 
(684 to 752)
5·0 
(2·4 to 7·7)
Cuba 41 964 
(36 486 to 48 735)
338 
(296 to 387)
12·5 
(8·0 to 17·7)
96 307 
(91 245 to 101 339)
683 
(646 to 719)
10·6 
(7·6 to 13·9)
Dominica 210 
(188 to 236)
284 
(254 to 319)
32·7 
(29·1 to 36·5)
458 
(434 to 481)
610 
(578 to 641)
35·5 
(31·6 to 40·0)
Dominican Republic 32 270 
(28 928 to 36 034)
308 
(277 to 343)
31·7 
(27·7 to 36·2)
65 016 
(61 686 to 68 195)
678 
(645 to 709)
34·1 
(30·7 to 37·7)
Grenada 333 
(296 to 373)
317 
(283 to 356)
29·8 
(26·2 to 33·5)
643 
(609 to 674)
645 
(612 to 674)
31·5 
(28·5 to 34·6)
Guyana 2297 
(2055 to 2582)
307 
(276 to 344)
15·4 
(11·7 to 19·3)
4176 
(3972 to 4380)
589 
(561 to 616)
19·1 
(16·5 to 22·0)
Haiti 31 804 
(27 952 to 36 334)
289 
(255 to 327)
20·1 
(12·3 to 31·0)
71 467 
(48 284 to 108 152)
748 
(530 to 1087)
69·6 
(20·6 to 144·6)
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Jamaica 7721 
(6895 to 8611)
268 
(239 to 299)
38·9 
(35·5 to 42·7)
16 275 
(15 350 to 17 055)
580 
(548 to 608)
38·2 
(33·7 to 42·4)
Puerto Rico 13 213 
(11 678 to 15 024)
346 
(307 to 391)
21·8 
(17·1 to 27·0)
31 248 
(29 568 to 32 767)
731 
(690 to 766)
23·4 
(19·7 to 27·1)
Saint Lucia 526 
(469 to 592)
291 
(260 to 328)
20·1 
(16·8 to 23·4)
1199 
(1141 to 1258)
632 
(602 to 663)
25·2 
(21·9 to 28·7)
Saint Vincent and the 
Grenadines
342 
(305 to 387)
312 
(279 to 352)
29·1 
(25·3 to 32·8)
698 
(661 to 731)
639 
(606 to 668)
30·9 
(27·2 to 34·7)
Suriname 1684 
(1511 to 1885)
313 
(281 to 351)
26·1 
(22·2 to 30·2)
3444 
(3284 to 3595)
652 
(623 to 680)
27·0 
(23·5 to 30·3)
Trinidad and Tobago 4111 
(3684 to 4589)
312 
(280 to 348)
24·9 
(19·7 to 29·9)
9781 
(9298 to 10 211)
661 
(628 to 691)
33·0 
(29·5 to 36·5)
Virgin Islands 343 
(306 to 389)
309 
(276 to 348)
15·2 
(11·6 to 18·8)
834 
(792 to 874)
640 
(607 to 672)
16·4 
(13·9 to 19·8)
Tropical Latin America 807 914 
(720 908 to 913 966)
382 
(340 to 432)
6·2 
(3·0 to 9·8)
1 648 860 
(1 572 072 to 1 728 016)
763 
(728 to 798)
5·4 
(3·0 to 7·5)
Brazil 786 433 
(701 498 to 889 704)
383 
(341 to 434)
5·6 
(2·4 to 9·2)
1 608 456 
(1 533 394 to 
1 684 669)
764 
(729 to 801)
4·9 
(2·4 to 7·0)
Paraguay 21 481 
(18 974 to 24 600)
330 
(293 to 376)
36·9 
(32·6 to 41·7)
40 404 
(38 084 to 42 978)
692 
(655 to 731)
33·7 
(29·4 to 38·3)
Southeast Asia, east Asia, 
and Oceania
6 356 051 
(5 736 733 to 7 010 413)
302 
(273 to 332)
31·1 
(26·8 to 35·5)
16 424 025 
(15 779 923 to 
17 082 254)
714 
(687 to 743)
43·0 
(41·0 to 45·4)
East Asia 4 481 454 
(4 033 188 to 4 949 337)
312 
(282 to 344)
33·3 
(28·5 to 38·3)
12 301 082 
(11 843 999 to 
12 776 357)
739 
(712 to 768)
43·5 
(41·4 to 45·7)
China 4 339 654 
(3 905 674 to 4 790 917)
313 
(283 to 345)
33·1 
(28·3 to 38·1)
11 931 974 
(11 487 676 to 
12 391 509)
742 
(715 to 771)
43·6 
(41·4 to 45·8)
North Korea 71 712 
(64 835 to 79 836)
267 
(241 to 297)
56·4 
(49·9 to 63·1)
163 389 
(156 812 to 170 561)
590 
(566 to 616)
54·1 
(50·3 to 57·6)
Taiwan (province of China) 70 088 
(63 129 to 77 594)
296 
(267 to 328)
26·2 
(21·3 to 31·9)
205 719 
(197 291 to 213 773)
708 
(679 to 737)
31·1 
(28·2 to 34·1)
Southeast Asia 1 843 182 
(1 667 459 to 2 039 489)
283 
(256 to 312)
27·1 
(20·9 to 32·0)
4 070 463 
(3 880 114 to 4 273 779)
649 
(620 to 680)
42·8 
(40·1 to 46·0)
Cambodia 41 142 
(37 163 to 45 610)
263 
(238 to 291)
25·3 
(6·8 to 38·0)
80 281 
(73 748 to 91 402)
615 
(560 to 713)
24·4 
(5·0 to 41·4)
Indonesia 672 105 
(606 726 to 743 145)
264 
(238 to 292)
25·2 
(21·4 to 29·1)
1 453 365 
(1 384 542 to 1 525 952)
595 
(569 to 624)
35·8 
(32·6 to 39·5)
Laos 17 757 
(16 038 to 19 746)
241 
(218 to 268)
17·7 
(–7·8 to 35·4)
29 003 
(27 652 to 30 510)
523 
(500 to 546)
53·6 
(49·8 to 57·0)
Malaysia 100 399 
(90 368 to 111 622)
324 
(292 to 358)
36·5 
(32·2 to 41·5)
219 095 
(209 068 to 229 686)
746 
(715 to 781)
42·9 
(40·1 to 45·4)
Maldives 772 
(699 to 859)
211 
(192 to 233)
7·2 
(3·6 to 10·5)
1638 
(1558 to 1716)
505 
(483 to 528)
20·5 
(18·3 to 23·3)
Mauritius 3375 
(3049 to 3722)
269 
(244 to 297)
43·8 
(39·1 to 48·6)
8810 
(8434 to 9178)
619 
(592 to 646)
52·3 
(48·8 to 55·6)
Myanmar 133 998 
(120 772 to 148 898)
250 
(225 to 278)
43·3 
(38·4 to 48·5)
309 036 
(282 463 to 348 950)
598 
(549 to 670)
72·3 
(60·5 to 88·9)
Philippines 285 035 
(256 711 to 318 916)
275 
(249 to 307)
29·7 
(21·0 to 38·3)
525 214 
(499 001 to 554 225)
589 
(562 to 621)
42·4 
(38·2 to 45·9)
Sri Lanka 63 643 
(57 818 to 70 087)
309 
(281 to 340)
–23·4 
(–49·2 to 0·2)
172 628 
(158 213 to 195 277)
794 
(727 to 897)
37·5 
(29·7 to 48·6)
Seychelles 306 
(278 to 339)
312 
(283 to 345)
37·7 
(33·4 to 42·4)
694 
(665 to 723)
692 
(663 to 720)
45·6 
(43·1 to 48·5)
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Thailand 244 221 
(218 841 to 271 818)
352 
(317 to 391)
28·2 
(23·8 to 32·7)
652 995 
(624 934 to 682 082)
812 
(776 to 848)
35·6 
(32·8 to 38·2)
Timor-Leste 2689 
(2426 to 2970)
235 
(213 to 260)
–26·3 
(–56·8 to 8·5)
5952 
(5049 to 7666)
711 
(593 to 930)
39·3 
(28·2 to 49·8)
Vietnam 275 305 
(247 741 to 307 255)
291 
(262 to 323)
50·4 
(46·0 to 55·0)
605 688 
(577 863 to 632 572)
644 
(616 to 672)
59·2 
(55·8 to 62·5)
Oceania 31 414 
(28 426 to 34 833)
282 
(256 to 312)
29·1 
(24·1 to 33·7)
52 480 
(49 980 to 55 147)
565 
(540 to 591)
39·8 
(37·6 to 42·4)
American Samoa 227 
(206 to 250)
290 
(264 to 320)
13·2 
(10·1 to 16·6)
444 
(422 to 466)
644 
(616 to 674)
17·6 
(14·9 to 20·2)
Federated States of 
Micronesia
273 
(247 to 302)
267 
(242 to 295)
28·0 
(24·2 to 32·1)
464 
(442 to 489)
545 
(521 to 571)
31·4 
(28·6 to 34·2)
Fiji 2181 
(1982 to 2409)
256 
(234 to 282)
40·0 
(35·7 to 44·4)
4599 
(4402 to 4812)
538 
(516 to 562)
43·5 
(40·8 to 45·9)
Guam 566 
(514 to 624)
326 
(296 to 359)
34·0 
(29·6 to 38·6)
1273 
(1219 to 1330)
726 
(695 to 758)
34·7 
(32·6 to 37·1)
Kiribati 283 
(255 to 316)
243 
(219 to 271)
42·2 
(38·0 to 46·9)
467 
(444 to 491)
481 
(459 to 503)
48·2 
(45·6 to 51·2)
Marshall Islands 197 
(179 to 218)
263 
(239 to 289)
31·4 
(27·2 to 35·8)
322 
(307 to 338)
528 
(505 to 552)
31·1 
(28·4 to 33·7)
Northern Mariana Islands 405 
(365 to 451)
307 
(279 to 338)
10·4 
(7·4 to 13·6)
758 
(720 to 798)
702 
(673 to 734)
11·9 
(9·8 to 13·9)
Papua New Guinea 22 356 
(20 209 to 24 797)
288 
(260 to 320)
27·0 
(21·0 to 32·2)
35 154 
(33 432 to 36 990)
566 
(540 to 592)
41·4 
(38·6 to 44·3)
Samoa 518 
(469 to 571)
261 
(237 to 287)
27·3 
(23·7 to 31·1)
944 
(899 to 996)
583 
(558 to 612)
36·5 
(33·2 to 40·5)
Solomon Islands 1593 
(1443 to 1765)
269 
(245 to 298)
33·4 
(29·3 to 37·6)
2481 
(2360 to 2611)
538 
(515 to 563)
38·5 
(36·2 to 41·0)
Tonga 288 
(261 to 320)
268 
(244 to 296)
18·4 
(14·2 to 22·7)
499 
(477 to 523)
565 
(542 to 589)
25·4 
(23·1 to 27·8)
Vanuatu 725 
(655 to 803)
259 
(235 to 287)
40·4 
(35·7 to 45·1)
1206 
(1148 to 1273)
539 
(514 to 566)
46·7 
(43·5 to 49·7)
North Africa and 
Middle East 
2 434 103 
(1 986 710 to 3 189 781)
412 
(340 to 528)
14·5 
(–1·1 to 43·0)
3 966 247 
(3 679 371 to 
4 400 997)
782 
(730 to 864)
1·3 
(–0·8 to 3·7)
Afghanistan 207 438 
(117 298 to 397 313)
564 
(331 to 1 046)
63·3 
(–0·4 to 166·9)
219 778 
(163 909 to 318 642)
953 
(670 to 1 458)
–10·5 
(–22·8 to 11·3)
Algeria 124 287 
(111 642 to 137 587)
310 
(278 to 343)
–7·5 
(–10·0 to –4·8)
259 395 
(246 483 to 272 456)
710 
(677 to 743)
–1·6 
(–3·6 to 0·7)
Bahrain 4748 
(4278 to 5231)
339 
(305 to 374)
–8·4 
(–11·6 to –5·1)
10 818 
(10 262 to 11 427)
796 
(759 to 835)
–2·1 
(–4·8 to 0·8)
Egypt 262 264 
(236 586 to 292 139)
281 
(254 to 312)
24·6 
(21·1 to 28·6)
484 935 
(461 177 to 509 082)
601 
(574 to 628)
23·2 
(20·3 to 26·4)
Iran 302 610 
(272 173 to 335 983)
372 
(335 to 411)
–32·7 
(–49·9 to –12·2)
701 593 
(652 604 to 773 884)
921 
(858 to 1013)
–7·8 
(–12·8 to –3·5)
Iraq 267 248 
(165 709 to 466 109)
633 
(407 to 1 097)
67·2 
(8·7 to 181·8)
314 391 
(253 102 to 440 165)
1134 
(908 to 1581)
–4·2 
(–12·8 to 5·1)
Jordan 27 961 
(22 479 to 37 776)
343 
(278 to 457)
4·3 
(–12·2 to 41·3)
40 959 
(38 745 to 43 436)
646 
(616 to 679)
–11·4 
(–13·8 to –8·5)
Kuwait 14 802 
(13 329 to 16 386)
376 
(339 to 415)
–32·3 
(–53·5 to –10·7)
33 516 
(31 700 to 35 329)
902 
(861 to 943)
–6·4 
(–9·7 to –4·0)
Lebanon 18 765 
(16 061 to 22 592)
329 
(282 to 395)
–44·6 
(–62·5 to –26·6)
63 264 
(49 117 to 92 756)
1099 
(849 to 1623)
–21·9 
(–30·4 to –12·0)
Libya 26 136 
(19 639 to 38 381)
420 
(318 to 617)
29·1 
(0·5 to 90·0)
47 418 
(41 783 to 57 143)
814 
(723 to 970)
6·8 
(–3·4 to 25·2)
(Table 1 continues on next page)
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Incidence Prevalence
2016 counts 2016 age-standardised 
rates (per 100 000)
Percentage change in 
age-standardised 
rates, 1990–2016
2016 counts 2016 age-standardised 
rates (per 100 000)
Percentage change in 
age-standardised rates, 
1990–2016
(Continued from previous page)
Morocco 95 064 
(85 330 to 105 706)
284 
(255 to 316)
0·5 
(–2·4 to 3·4)
212 653 
(203 045 to 224 043)
647 
(618 to 680)
5·9 
(3·8 to 8·5)
Oman 20 498 
(18 259 to 22 719)
427 
(383 to 475)
–5·5 
(–9·0 to –2·0)
41 920 
(39 721 to 43 961)
991 
(945 to 1036)
–1·1 
(–3·0 to 0·9)
Palestine 16 165 
(14 415 to 18 200) 
284 
(256 to 318)
–2·8 
(–18·9 to 9·5)
25 590 
(22 870 to 30 171)
714 
(629 to 875)
–1·2 
(–10·3 to 7·7)
Qatar 11 778 
(10 504 to 13 139)
484 
(436 to 535)
–2·3 
(–5·5 to 0·8)
24 779 
(23 437 to 26 188)
1155 
(1102 to 1210)
0·0 
(–2·2 to 1·9)
Saudi Arabia 119 832 
(107 918 to 132 057)
380 
(341 to 419)
–13·5 
(–15·3 to –11·5)
243 943 
(233 302 to 255 668)
855 
(821 to 892)
–11·1 
(–12·5 to –10·0)
Sudan 126 030 
(109 808 to 146 687)
306 
(268 to 352)
6·7 
(–0·6 to 14·5)
199 309 
(187 481 to 215 246)
639 
(605 to 686)
12·9 
(10·4 to 15·8)
Syria 262 602 
(93 725 to 553 607)
1322 
(481 to 2 779)
424·8 
(90·8 to 1 029·7)
149 597 
(109 414 to 218 593)
917 
(696 to 1288)
60·3 
(26·7 to 117·7)
Tunisia 34 436 
(30 908 to 38 256)
314 
(281 to 349)
4·4 
(1·4 to 8·2)
80 306 
(76 207 to 84 356)
699 
(664 to 734)
7·1 
(4·2 to 10·7)
Turkey 248 553 
(222 612 to 277 292)
316 
(283 to 352)
–15·7 
(–19·3 to –10·7)
557 595 
(531 362 to 584 590)
708 
(676 to 742)
–13·2 
(–16·3 to –10·2)
United Arab Emirates 46 220 
(41 326 to 51 437)
464 
(417 to 513)
–6·8 
(–9·2 to –4·4)
102 902 
(97 674 to 108 666)
1074 
(1028 to 1125)
–4·1 
(–6·3 to –2·1)
Yemen 194 241 
(130 687 to 327 977)
626 
(427 to 1051)
99·0 
(35·8 to 234·4)
147 165 
(134 214 to 168 397)
708 
(659 to 783)
7·8 
(3·0 to 15·6)
South Asia 7 039 830 
(6 292 303 to 7 812 364)
439 
(393 to 488)
4·4 
(2·4 to 6·6)
12 366 812 
(11 871 688 to 
12 866 592)
828 
(794 to 860)
16·7 
(15·7 to 17·8)
Bangladesh 540 467 
(485 923 to 599 958)
343 
(309 to 383)
12·9 
(9·6 to 16·3)
980 717 
(935 604 to 1 031 234)
698 
(666 to 732)
29·5 
(26·4 to 33·2)
Bhutan 3214 
(2872 to 3589)
426 
(379 to 477)
2·1 
(–0·5 to 4·7)
5489 
(5233 to 5756)
811 
(777 to 847)
7·6 
(5·2 to 10·0)
India 5 641 697 
(5 039 029 to 6 262 015)
455 
(406 to 505)
2·3 
(0·1 to 4·6)
9 965 355 
(9 558 481 to 
10 358 885)
846 
(811 to 879)
14·7 
(13·8 to 15·7)
Nepal 108 610 
(96 933 to 121 246)
382 
(340 to 427)
3·9 
(0·9 to 7·1)
181 820 
(173 484 to 191 290)
751 
(717 to 788)
20·3 
(17·3 to 23·7)
Pakistan 745 843 
(669 513 to 830 822)
401 
(361 to 446)
19·9 
(16·5 to 23·2)
1 233 430 
(1 174 231 to 1 291 274)
803 
(769 to 837)
26·5 
(23·7 to 30·0)
Sub-Saharan Africa 2 956 908 
(2 659 347 to 3 286 997)
326 
(293 to 363)
–11·8 
(–20·3 to –6·7)
4 182 169 
(3 987 073 to 
4 395 220)
621 
(594 to 649)
0·7 
(–0·3 to 1·8)
Southern sub-Saharan 
Africa
251 795 
(227 351 to 279 669)
332 
(300 to 368)
–14·4 
(–18·0 to –12·0)
420 050 
(401 203 to 441 118)
640 
(614 to 670)
–15·2 
(–16·2 to –14·3)
Botswana 7864 
(7032 to 8785)
351 
(316 to 391)
17·1 
(14·2 to 20·1)
12 941 
(12 262 to 13 600)
675 
(643 to 706)
16·0 
(14·2 to 18·0)
eSwatini 4735 
(4232 to 5305)
365 
(326 to 407)
17·0 
(13·3 to 20·8)
6370 
(6051 to 6696)
646 
(617 to 675)
8·3 
(6·5 to 10·2)
Lesotho 7016 
(6310 to 7810)
336 
(304 to 372)
25·7 
(22·4 to 29·2)
9080 
(8651 to 9546)
529 
(507 to 555)
9·0 
(7·0 to 11·2)
Namibia 7400 
(6646 to 8200)
296 
(266 to 326)
–0·2 
(–2·8 to 2·4)
11 413 
(10 830 to 11 979)
578 
(551 to 603)
2·1 
(0·7 to 3·6)
South Africa 185 015 
(167 062 to 205 569)
352 
(318 to 390)
–18·8 
(–22·9 to –15·9)
327 583 
(313 064 to 344 174)
680 
(652 to 712)
–19·3 
(–20·3 to –18·3)
Zimbabwe 39 766 
(35 598 to 44 047)
271 
(245 to 300)
2·9 
(0·9 to 5·0)
52 663 
(50 084 to 55 611)
471 
(452 to 492)
0·7 
(–1·1 to 2·5)
Western sub-Saharan Africa 1 158 340 
(1 040 158 to 1 293 825)
316 
(284 to 353)
–2·6 
(–4·9 to –0·7)
1 614 512 
(1 537 783 to 1 696 546)
597 
(572 to 622)
3·1 
(1·9 to 4·4)
(Table 1 continues on next page)
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Incidence Prevalence
2016 counts 2016 age-standardised 
rates (per 100 000)
Percentage change in 
age-standardised 
rates, 1990–2016
2016 counts 2016 age-standardised 
rates (per 100 000)
Percentage change in 
age-standardised rates, 
1990–2016
(Continued from previous page)
Benin 33 501 
(30 129 to 37 297)
327 
(293 to 364)
4·6 
(1·7 to 7·6)
47 011 
(44 631 to 49 362)
613 
(585 to 638)
7·7 
(5·2 to 10·1)
Burkina Faso 53 214 
(47 530 to 59 321)
312 
(278 to 349)
–0·6 
(–3·2 to 2·1)
69 252 
(65 694 to 72 704)
567 
(542 to 592)
6·3 
(4·3 to 8·6)
Cameroon 70 982 
(63 788 to 79 440)
320 
(286 to 359)
3·0 
(0·0 to 6·2)
95 352 
(90 299 to 100 578)
572 
(546 to 598)
0·5 
(–1·4 to 2·7)
Cape Verde 1654 
(1495 to 1838)
304 
(275 to 337)
12·2 
(9·7 to 14·8)
2810 
(2673 to 2944)
626 
(600 to 653)
16·0 
(13·5 to 18·6)
Chad 42 615 
(38 197 to 47 636)
315 
(282 to 351)
–7·6 
(–22·9 to 2·7)
54 599 
(51 499 to 58 150)
595 
(564 to 631)
5·1 
(2·0 to 7·7)
Côte d’Ivoire 71 655 
(64 027 to 80 338)
344 
(307 to 385)
–5·3 
(–7·9 to –2·6)
99 313 
(93 967 to 104 562)
617 
(589 to 644)
–3·0 
(–5·1 to –0·9)
The Gambia 5471 
(4879 to 6116)
291 
(261 to 325)
–9·8 
(–11·7 to –8·0)
7266 
(6889 to 7683)
552 
(528 to 578)
–9·4 
(–11·5 to –7·4)
Ghana 84 274 
(75 885 to 93 620)
329 
(295 to 367)
12·5 
(10·0 to 15·1)
125 387 
(119 141 to 131 582)
614 
(587 to 640)
15·9 
(13·5 to 18·4)
Guinea 35 050 
(31 420 to 39 047)
297 
(267 to 331)
–5·1 
(–7·2 to –2·8)
48 739 
(46 352 to 51 196)
539 
(516 to 562)
–4·7 
(–6·9 to –2·2)
Guinea-Bissau 5715 
(5146 to 6362)
328 
(295 to 365)
–7·8 
(–9·5 to –6·1)
7776 
(7400 to 8173)
567 
(544 to 591)
–4·7 
(–6·7 to –2·7)
Liberia 11 400 
(10 217 to 12 762)
270 
(242 to 302)
–61·6 
(–77·5 to –41·0)
17 961 
(16 439 to 20 466)
558 
(512 to 634)
–4·3 
(–11·0 to 4·7)
Mali 49 132 
(43 999 to 54 775)
292 
(263 to 325)
–5·0 
(–8·6 to –2·3)
64 365 
(61 076 to 68 253)
557 
(532 to 586)
6·6 
(3·5 to 11·1)
Mauritania 12 094 
(10 836 to 13 462)
321 
(288 to 358)
–11·3 
(–22·4 to –3·5)
19 189 
(18 276 to 20 120)
642 
(614 to 670)
5·7 
(3·6 to 7·9)
Niger 52 541 
(47 077 to 58 407)
281 
(253 to 314)
–11·2 
(–14·2 to –8·7)
66 915 
(63 772 to 70 348)
521 
(498 to 543)
–5·6 
(–7·8 to –3·6)
Nigeria 546 313 
(488 793 to 609 609)
319 
(286 to 358)
–0·6 
(–3·3 to 2·6)
772 539 
(731 537 to 814 574)
619 
(591 to 648)
3·8 
(1·7 to 6·0)
São Tomé and Príncipe 670 
(603 to 748)
360 
(324 to 402)
5·9 
(3·0 to 8·7)
945 
(897 to 992)
705 
(673 to 737)
6·3 
(3·8 to 8·7)
Senegal 44 145 
(39 611 to 48 997)
314 
(280 to 350)
–0·4 
(–3·1 to 2·5)
61 131 
(58 199 to 64 314)
586 
(560 to 612)
2·4 
(–0·1 to 4·6)
Sierra Leone 17 879 
(16 024 to 19 972)
299 
(268 to 334)
–5·1 
(–7·3 to –3·0)
25 965 
(24 414 to 28 059)
573 
(541 to 620)
0·9 
(–3·5 to 8·5)
Togo 20 024 
(17 885 to 22 273)
296 
(265 to 330)
–1·9 
(–4·4 to 0·8)
27 967 
(26 541 to 29 459)
536 
(513 to 559)
–1·9 
(–3·9 to 0·4)
Eastern sub-Saharan Africa 1 181 878 
(1 055 453 to 1 317 176)
337 
(302 to 377)
–19·1 
(–33·5 to –9·4)
1 649 534 
(1 564 002 to 1 748 871)
640 
(608 to 680)
5·3 
(3·4 to 7·0)
Burundi 37 392 
(33 413 to 41 982)
363 
(324 to 408)
3·0 
(0·5 to 5·6)
51 646 
(48 379 to 56 131)
689 
(646 to 748)
24·3 
(18·8 to 34·5)
Comoros 2436 
(2192 to 2719)
339 
(304 to 377)
–22·2 
(–24·0 to –20·1)
3746 
(3554 to 3940)
661 
(632 to 690)
–16·8 
(–18·6 to –14·8)
Djibouti 3282 
(2949 to 3671)
364 
(326 to 408)
–9·1 
(–16·4 to –4·4)
5163 
(4902 to 5411)
708 
(676 to 738)
–1·2 
(–3·1 to 1·0)
Eritrea 16 867 
(15 110 to 18 875)
357 
(319 to 400)
–1·4 
(–4·3 to 1·4)
24 312 
(22 780 to 26 223)
679 
(640 to 728)
15·2 
(10·5 to 22·6)
Ethiopia 314 622 
(281 760 to 350 817)
343 
(307 to 382)
–43·4 
(–62·2 to –25·4)
456 884 
(430 726 to 485 886)
659 
(624 to 703)
2·4 
(–2·7 to 6·0)
Kenya 148 509 
(133 090 to 166 370)
349 
(313 to 391)
8·8 
(7·7 to 9·8)
216 411 
(206 413 to 226 979)
669 
(642 to 696)
12·9 
(12·1 to 13·9)
Madagascar 70 496 
(63 093 to 78 880)
305 
(272 to 342)
–5·6 
(–8·3 to –2·8)
98 994 
(93 993 to 104 236)
567 
(540 to 593)
–2·6 
(–4·8 to –0·3)
(Table 1 continues on next page)
Articles
66 www.thelancet.com/neurology   Vol 18   January 2019
collaboration that quantifies the effects of hundreds of 
diseases, injuries, and risk factors around the world, 
producing annual estimates of all-cause mortality, causes 
of death, non-fatal health outcomes, and risk factors. 
Within the GBD framework, estimates for TBI and SCI 
burden have not previously been available as reported 
results. Instead, these nature-of-injury codes were in-
corporated as part of the analytic process that computed 
disability and results were ultimately provided only by 
cause (eg, falls) rather than by nature of injury (eg, TBI). 
Here, we describe an approach for estimation of nature-
specific non-fatal burden estimates for all injuries, and 
report the incidence, prevalence, and years of life lived 
with disability (YLDs) for TBI and SCI, as well as the 
proportion of TBI and SCI caused by different injuries 
by region.
Methods
Overview
Our approach to measuring TBI and SCI was developed 
within the GBD 2016 study framework. In the GBD 2016 
study, standardised analytic methods were used to 
estimate incidence, prevalence, and YLDs by age, sex, 
cause, year, and location. The study was an attempt to use 
all accessible information about disease and injury 
occurrence, clinical course, and severity that passed a set 
of inclusion criteria. The comparability of data was 
optimised by adjusting for different case definitions, 
enforcing consistency between data for prevalence, 
incidence, and cause of death estimates, and predicting 
estimates for locations with sparse data by borrowing 
information from other locations and covariates. These 
methods, data, and criteria are described in more detail in 
other GBD 2016 reports.3,14–17
Detailed elements of the GBD methods for meas-
urement of TBI and SCI (including case definitions and 
severity definitions), a flowchart for our TBI and SCI 
estimation, and overall GBD study methods are in 
appendix 1. The measurement of TBI and SCI burden had 
two key deviations from the standard GBD framework. 
First, the GBD cause hierarchy categorised both TBI and 
SCI as being a nature of injury as opposed to a cause of 
Incidence Prevalence
2016 counts 2016 age-standardised 
rates (per 100 000)
Percentage change in 
age-standardised 
rates, 1990–2016
2016 counts 2016 age-standardised 
rates (per 100 000)
Percentage change in 
age-standardised rates, 
1990–2016
(Continued from previous page)
Malawi 45 111 
(40 282 to 50 765)
273 
(244 to 307)
–13·1 
(–15·3 to –10·8)
56 744 
(53 648 to 60 217)
478 
(455 to 502)
–9·8 
(–12·3 to –7·7)
Mozambique 86 051 
(77 161 to 95 938)
333 
(298 to 371)
1·5 
(–11·2 to 9·5)
116 779 
(109 146 to 126 995)
629 
(584 to 697)
4·2 
(–5·1 to 11·2)
Rwanda 33 114 
(29 559 to 37 120)
297 
(265 to 334)
–35·1 
(–50·5 to –24·7)
63 878 
(52 403 to 85 437)
782 
(633 to 1065)
27·0 
(4·1 to 73·2)
Somalia 38 718 
(32 227 to 50 226)
402 
(339 to 505)
–11·6 
(–17·6 to –6·7)
45 828 
(42 334 to 51 096)
645 
(598 to 719)
1·2 
(–2·3 to 6·6)
South Sudan 46 491 
(41 340 to 52 564)
383 
(341 to 434)
–29·0 
(–49·5 to –9·0)
63 707 
(59 090 to 70 275)
723 
(674 to 797)
1·1 
(–3·0 to 7·3)
Tanzania 166 283 
(148 670 to 186 579)
332 
(298 to 371)
–3·1 
(–5·3 to –0·8)
225 251 
(213 622 to 237 194)
615 
(588 to 643)
1·7 
(–0·5 to 4·0)
Uganda 116 067 
(103 532 to 129 901)
316 
(283 to 354)
0·3 
(–4·1 to 3·8)
149 404 
(139 610 to 161 903)
609 
(568 to 674)
9·2 
(–0·6 to 16·7)
Zambia 55 681 
(49 801 to 62 201)
381 
(341 to 424)
7·1 
(4·3 to 10·0)
69 654 
(66 142 to 73 339)
647 
(619 to 675)
4·6 
(2·6 to 6·8)
Central sub-Saharan Africa 364 894 
(327 646 to 405 768)
331 
(296 to 369)
–7·4 
(–11·7 to –4·5)
498 074 
(473 461 to 526 322)
637 
(607 to 673)
2·5 
(0·8 to 4·7)
Angola 89 553 
(80 374 to 99 729)
378 
(338 to 424)
–12·8 
(–27·2 to –3·2)
123 421 
(115 993 to 132 673)
772 
(726 to 841)
6·4 
(1·5 to 10·2)
Central African Republic 14 436 
(12 954 to 16 183)
299 
(268 to 335)
5·7 
(1·6 to 11·2)
18 918 
(17 855 to 20 081)
487 
(464 to 513)
5·7 
(2·6 to 9·9)
Congo (Brazzaville) 15 810 
(14 211 to 17 546)
356 
(318 to 397)
–2·4 
(–4·4 to –0·2)
23 976 
(22 503 to 25 886)
711 
(669 to 769)
15·3 
(10·3 to 24·3)
Democratic Republic of the 
Congo
235 694 
(211 454 to 262 391)
315 
(283 to 351)
–6·6 
(–8·6 to –4·6)
316 583 
(300 808 to 333 679)
599 
(571 to 627)
–0·5 
(–3·1 to 3·0)
Equatorial Guinea 3144 
(2808 to 3501)
402 
(359 to 452)
16·1 
(12·5 to 20·0)
5148 
(4920 to 5371)
799 
(765 to 831)
39·4 
(36·4 to 42·4)
Gabon 6257 
(5600 to 6956)
370 
(331 to 411)
–12·0 
(–14·1 to –9·8)
10 028 
(9590 to 10 472)
732 
(701 to 761)
–4·0 
(–5·7 to –2·4)
95% uncertainty intervals are in parentheses. SDI=Socio-demographic Index.
Table 1: Incidence and prevalence of traumatic brain injury in 2016, and percentage change in age-standardised rates by location, 1990–2016
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Incidence Prevalence
2016 counts 2016 
age-standardised rates 
(per 100 000)
Percentage change 
in age-standardised 
rates, 1990–2016
2016 counts 2016 age-standardised 
rates (per 100 000)
Percentage change in 
age-standardised rates, 
1990–2016
Global 934 951 
(780 963 to 1 155 187)
13 
(11 to 16)
–3·6 
(–7·4 to 4·0)
27 042 505 
(24 976 608 to 
30 148 230)
368 
(340 to 409)
–0·2 
(–2·1 to 2·7)
High SDI 276 308 
(216 293 to 355 713)
25 
(20 to 31)
–3·6 
(–6·9 to –0·5)
9 247 664 
(8 524 049 to 
9 989 539)
760 
(698 to 827)
–1·5 
(–3·1 to –0·1)
High-middle SDI 155 063 
(128 957 to 184 025)
13 
(11 to 16)
–13·7 
(–18·7 to –10·0)
5 394 307 
(4 994 153 to 6 042 158)
420 
(389 to 469)
–4·8 
(–6·4 to –3·3)
Middle SDI 176 312 
(149 499 to 209 614)
8 
(7 to 9)
5·8 
(–0·9 to 11·7)
5 576 932 
(5 244 937 to 5 941 725)
231 
(217 to 246)
25·6 
(23·4 to 28·0)
Low-middle SDI 242 480 
(189 305 to 340 476)
12 
(9 to 16)
17·9 
(4·2 to 54·0)
5 141 936 
(4 571 709 to 6 349 080)
260 
(233 to 319)
22·6 
(19·5 to 28·1)
Low SDI 89 536 
(65 824 to 142 240)
12 
(9 to 18)
–20·0 
(–33·2 to –10·1)
1 795 869 
(1 327 167 to 2 961 901)
304 
(220 to 519)
14·2 
(8·1 to 25·5)
High income 287 206 
(223 675 to 372 032)
25 
(20 to 32)
–4·3 
(–7·7 to –1·1)
9 699 029 
(8 946 042 to 
10 481 324)
776 
(713 to 846)
–2·0 
(–3·6 to –0·6)
High-income North America 101 259 
(79 044 to 129 722)
26 
(20 to 33)
2·9 
(–3·2 to 9·0)
2 959 275 
(2 725 268 to 3 165 768)
709 
(650 to 761)
–6·5 
(–9·9 to –2·6)
Canada 9654 
(7533 to 12 401)
25 
(20 to 31)
–2·5 
(–7·3 to 1·9)
324 689 
(298 545 to 349 527)
752 
(685 to 811)
0·5 
(–2·7 to 3·8)
Greenland 15 
(12 to 19)
31 
(24 to 39)
–16·5 
(–19·0 to –14·0)
388 
(357 to 416)
704 
(644 to 759)
–2·1 
(–5·5 to 1·5)
USA 91 556 
(71 406 to 117 479)
26 
(20 to 33)
3·7 
(–2·7 to 10·5)
2 633 160 
(2 427 190 to 2 818 818)
704 
(646 to 756)
–7·3 
(–11·1 to –3·0)
Australasia 6612 
(5191 to 8442)
23 
(18 to 29)
–2·2 
(–8·0 to 2·9)
240 093 
(220 533 to 259 720)
745 
(682 to 811)
3·3 
(–0·3 to 6·9)
Australia 5556 
(4366 to 7090)
23 
(18 to 28)
–1·3 
(–7·1 to 4·1)
201 658 
(185 041 to 218 197)
742 
(679 to 809)
3·9 
(–0·1 to 7·9)
New Zealand 1057 
(830 to 1351)
23 
(18 to 29)
–6·4 
(–12·3 to –0·9)
38 436 
(35 415 to 41 681)
759 
(695 to 828)
0·3 
(–3·5 to 5·4)
High-income Asia Pacific 51 251 
(40 229 to 65 487)
25 
(20 to 32)
–9·6 
(–13·6 to –5·7)
1 831 823 
(1 686 204 to 1 996 895)
821 
(747 to 907)
1·1 
(–1·3 to 3·9)
Brunei 124 
(98 to 154)
32 
(25 to 40)
–13·8 
(–17·7 to –9·9)
4018 
(3641 to 4463)
922 
(840 to 1021)
–6·9 
(–9·8 to –3·9)
Japan 36 218 
(28 255 to 46 493)
25 
(20 to 31)
–5·1 
(–10·0 to –1·0)
1 306 337 
(1 202 409 to 1 424 185)
824 
(749 to 913)
5·0 
(2·1 to 8·8)
Singapore 1000 
(786 to 1269)
26 
(21 to 33)
2·0 
(–2·5 to 6·5)
39 555 
(36 218 to 43 598)
875 
(797 to 969)
15·6 
(10·5 to 21·3)
South Korea 13 909 
(10 890 to 17 539)
27 
(21 to 34)
–17·2 
(–21·3 to –12·3)
481 913 
(440 648 to 527 192)
811 
(738 to 894)
–8·1 
(–11·6 to –4·4)
Western Europe 115 958 
(88 458 to 151 615)
26 
(20 to 33)
–6·8 
(–10·8 to –3·5)
4 297 097 
(3 965 806 to 4 706 288)
854 
(780 to 945)
0·3 
(–1·6 to 2·5)
Andorra 21 
(16 to 28)
26 
(20 to 33)
4·0 
(1·4 to 6·9)
834 
(763 to 915)
886 
(805 to 985)
7·0 
(3·3 to 10·8)
Austria 2614 
(1982 to 3459)
29 
(22 to 37)
–14·8 
(–19·0 to –10·3)
97 310 
(88 649 to 107 961)
937 
(853 to 1051)
–5·7 
(–8·9 to –1·3)
Belgium 3784 
(2863 to 5077)
30 
(23 to 39)
3·7 
(–3·3 to 10·2)
121 148 
(110 972 to 133 190)
908 
(827 to 1008)
3·7 
(0·0 to 7·8)
Cyprus 239 
(186 to 303)
27 
(21 to 34)
–2·4 
(–7·0 to 1·8)
9060 
(8244 to 9999)
887 
(803 to 984)
5·0 
(1·6 to 8·7)
Denmark 1582 
(1199 to 2081)
27 
(21 to 35)
–10·9 
(–15·6 to –6·0)
57 680 
(52 720 to 63 666)
876 
(793 to 979)
5·1 
(0·6 to 9·2)
Finland 1963 
(1476 to 2638)
32 
(25 to 42)
0·5 
(–4·3 to 5·4)
64 375 
(58 841 to 70 664)
977 
(884 to 1084)
11·3 
(7·5 to 15·7)
France 19 918 
(14 899 to 26 506)
27 
(21 to 35)
–12·4 
(–17·1 to –7·7)
643 671 
(592 262 to 702 838)
855 
(781 to 943)
–5·5 
(–8·8 to –1·7)
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Germany 22 047 
(16 728 to 28 901)
26 
(20 to 33)
–5·6 
(–10·7 to –0·9)
837 659 
(768 281 to 921 948)
842 
(765 to 939)
3·0 
(–1·0 to 7·3)
Greece 2627 
(2036 to 3381)
25 
(20 to 32)
–9·7 
(–13·7 to –5·8)
111 122 
(102 610 to 121 509)
860 
(787 to 949)
–3·7 
(–7·0 to –0·5)
Iceland 84 
(65 to 108)
25 
(20 to 32)
–1·2 
(–5·6 to 3·2)
3138 
(2868 to 3465)
864 
(786 to 959)
7·6 
(3·3 to 12·4)
Ireland 1250 
(964 to 1625)
28 
(21 to 35)
5·4 
(–0·8 to 10·7)
48 263 
(43 550 to 53 544)
961 
(862 to 1073)
13·3 
(8·7 to 18·4)
Israel 1969 
(1532 to 2513)
24 
(18 to 30)
0·2 
(–9·9 to 6·3)
73 637 
(63 187 to 94 545)
913 
(782 to 1179)
18·9 
(10·6 to 32·3)
Italy 16 889 
(13 033 to 21 903)
27 
(21 to 34)
–6·0 
(–9·9 to –1·8)
657 779 
(602 165 to 725 620)
893 
(810 to 999)
0·9 
(–2·9 to 4·8)
Luxembourg 158 
(121 to 206)
27 
(20 to 34)
–21·0 
(–25·3 to –16·9)
5725 
(5240 to 6266)
854 
(778 to 941)
–13·6 
(–16·8 to –10·1)
Malta 109 
(84 to 141)
26 
(21 to 34)
–7·8 
(–11·0 to –4·5)
4474 
(4088 to 4920)
905 
(820 to 1003)
–0·1 
(–4·0 to 3·3)
Netherlands 4019 
(3104 to 5168)
23 
(18 to 29)
3·0 
(–2·5 to 9·1)
152 583 
(141 164 to 164 905)
764 
(702 to 833)
8·7 
(4·1 to 13·7)
Norway 1498 
(1139 to 1981)
27 
(21 to 35)
–0·5 
(–4·8 to 4·2)
52 434 
(47 800 to 58 063)
876 
(795 to 982)
9·7 
(5·5 to 14·3)
Portugal 2425 
(1888 to 3137)
22 
(18 to 28)
–23·3 
(–28·1 to –18·8)
92 650 
(85 596 to 100 266)
730 
(671 to 797)
–18·2 
(–22·0 to –14·4)
Spain 11 337 
(8741 to 14 624)
24 
(19 to 31)
–6·4 
(–11·9 to –1·0)
464 843 
(427 508 to 508 351)
841 
(768 to 931)
1·0 
(–2·9 to 5·8)
Sweden 2719 
(2083 to 3556)
26 
(20 to 34)
2·9 
(–1·8 to 7·0)
101 699 
(92 140 to 113 327)
903 
(811 to 1017)
7·2 
(2·8 to 11·4)
Switzerland 2379 
(1793 to 3115)
25  
(20 to 33)
–28·3 
(–34·0 to –23·3)
79 465 
(73 587 to 85 786)
780 
(718 to 847)
–23·9 
(–28·0 to –19·9)
UK 16 215 
(12 431 to 21 182)
25 
(19 to 32)
–0·4 
(–4·5 to 2·8)
613 245 
(561 180 to 677 232)
833 
(754 to 929)
2·5 
(0·2 to 4·8)
Southern Latin America 12 125 
(9601 to 15 163)
18 
(15 to 23)
9·6 
(6·1 to 12·6)
370 741 
(343 020 to 399 059)
548 
(507 to 591)
19·3 
(15·6 to 23·5)
Argentina 8086 
(6429 to 10 010)
18 
(15 to 23)
10·3 
(5·5 to 14·5)
246 246 
(227 798 to 265 490)
556 
(514 to 600)
20·5 
(15·8 to 26·0)
Chile 3362 
(2662 to 4286)
18 
(14 to 23)
4·9 
(1·5 to 8·1)
104 731 
(96 919 to 112 518)
534 
(493 to 575)
15·2 
(11·2 to 19·2)
Uruguay 677 
(533 to 851)
19 
(15 to 23)
14·6 
(11·1 to 18·3)
19 745 
(18 265 to 21 341)
534 
(492 to 578)
20·9 
(16·5 to 26·4)
Central Europe, eastern Europe, 
and central Asia 
77 852 
(63 320 to 94 211)
18 
(15 to 22)
–5·2 
(–7·3 to –3·1)
2 371 936 
(2 210 605 to 
2 553 070)
513 
(477 to 554)
2·5 
(–0·1 to 7·0)
Eastern Europe 41 674 
(34 038 to 50 176)
19 
(16 to 23)
–4·2 
(–7·1 to –1·4)
1 222 360 
(1 141 216 to 1 306 976)
510 
(474 to 547)
–1·0 
(–3·9 to 2·7)
Belarus 2111 
(1719 to 2578)
22 
(18 to 26)
14·2 
(10·3 to 18·3)
62 524 
(58 133 to 66 705)
568 
(527 to 609)
13·8 
(10·1 to 17·6)
Estonia 249 
(201 to 304)
19 
(15 to 23)
–18·0 
(–22·1 to –13·6)
8391 
(7794 to 9006)
549 
(507 to 592)
–4·0 
(–7·6 to –0·4)
Latvia 383 
(310 to 470)
19 
(15 to 23)
–20·4 
(–24·1 to –16·4)
11 905 
(11 114 to 12 653)
516 
(480 to 552)
–9·5 
(–12·1 to –6·6)
Lithuania 653 
(527 to 798)
21 
(18 to 26)
–3·8 
(–7·6 to 0·4)
19 428 
(18 014 to 20 800)
570 
(526 to 614)
1·8 
(–2·1 to 5·5)
Moldova 652 
(537 to 776)
16 
(13 to 19)
–15·7 
(–19·2 to –11·8)
20 939 
(19 342 to 22 699)
458 
(422 to 497)
–5·0 
(–9·0 to 0·3)
Russia 29 681 
(24 253 to 35 758)
20 
(16 to 24)
–4·1 
(–7·8 to –0·7)
847 799 
(789 586 to 907 826)
514 
(478 to 552)
–1·3 
(–4·7 to 3·1)
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Ukraine 7945 
(6532 to 9573)
18 
(15 to 21)
–6·3 
(–9·7 to –2·8)
251 374 
(235 107 to 268 367)
484 
(451 to 519)
–2·6 
(–6·3 to 1·7)
Central Europe 24 512 
(19 365 to 30 562)
20 
(16 to 25)
–3·3 
(–6·4 to –0·6)
812 242 
(750 130 to 881 919)
597 
(549 to 653)
12·1 
(8·8 to 17·9)
Albania 463 
(369 to 567)
16 
(13 to 20)
10·4 
(5·3 to 15·3)
17 030 
(15 238 to 19 542)
537 
(480 to 622)
20·0 
(11·8 to 36·8)
Bosnia and Herzegovina 621 
(497 to 772)
17 
(14 to 21)
32·5 
(27·6 to 38·0)
33 351 
(25 724 to 49 144)
739 
(568 to 1097)
91·8 
(50·9 to 184·2)
Bulgaria 1331 
(1055 to 1664)
19 
(15 to 23)
–6·1 
(–10·4 to –1·8)
47 216 
(43 288 to 50 931)
553 
(503 to 598)
0·0 
(–3·7 to 3·5)
Croatia 874 
(687 to 1101)
18 
(15 to 22)
–3·7 
(–9·7 to 2·2)
27 754 
(24 164 to 34 570)
545 
(472 to 684)
13·6 
(–0·4 to 46·6)
Czech Republic 2691 
(2131 to 3348)
24 
(20 to 30)
–4·5 
(–10·0 to 1·1)
91 860 
(84 086 to 99 449)
728 
(662 to 791)
19·1 
(14·6 to 24·6)
Hungary 2256 
(1759 to 2863)
21 
(16 to 26)
–17·4 
(–22·5 to –12·8)
64 731 
(59 089 to 69 980)
554 
(504 to 603)
4·1 
(–0·6 to 8·5)
Macedonia 350 
(276 to 430)
17 
(14 to 21)
17·5 
(12·9 to 21·9)
12 171 
(11 089 to 13 251)
518 
(470 to 567)
21·7 
(16·7 to 27·2)
Montenegro 117 
(94 to 144)
19 
(15 to 23)
8·0 
(4·8 to 11·4)
3952 
(3633 to 4262)
564 
(515 to 612)
11·6 
(8·2 to 15·7)
Poland 8501 
(6733 to 10 627)
21 
(17 to 26)
0·9 
(–3·6 to 5·0)
267 715 
(247 729 to 289 959)
589 
(543 to 641)
15·1 
(11·2 to 19·5)
Romania 3972 
(3142 to 4942)
20 
(16 to 25)
–10·3 
(–15·0 to –5·9)
129 774 
(119 600 to 139 154)
571 
(525 to 617)
–5·5 
(–9·3 to –2·0)
Serbia 1542 
(1220 to 1916)
18 
(14 to 22)
13·7 
(10·3 to 17·4)
60 445 
(52 192 to 75 281)
604 
(518 to 761)
36·8 
(20·9 to 72·7)
Slovakia 1189 
(937 to 1487)
21 
(17 to 26)
–9·4 
(–13·1 to –5·5)
37 606 
(34 645 to 40 508)
588 
(538 to 637)
5·7 
(2·1 to 9·4)
Slovenia 605 
(465 to 778)
26 
(20 to 33)
–0·8 
(–6·9 to 7·3)
18 638 
(17 160 to 19 922)
732 
(670 to 785)
14·5 
(10·3 to 18·8)
Central Asia 11 666 
(9682 to 13 817)
13 
(11 to 16)
–0·9 
(–3·1 to 1·4)
337 334 
(311 213 to 368 474)
391 
(361 to 425)
5·4 
(1·8 to 12·0)
Armenia 381 
(312 to 456)
13 
(11 to 15)
–12·5 
(–16·5 to –8·6)
17 219 
(13 820 to 22 659)
518 
(418 to 678)
–15·9 
(–23·6 to –7·2)
Azerbaijan 1233 
(1023 to 1470)
13 
(10 to 15)
–3·0 
(–6·3 to 0·4)
41 913 
(37 773 to 48 658)
407 
(368 to 469)
14·1 
(5·8 to 30·9)
Georgia 514 
(422 to 615)
13 
(11 to 15)
–5·6 
(–9·2 to –2·0)
17 389 
(15 704 to 20 381)
395 
(355 to 464)
4·3 
(–4·5 to 22·4)
Kazakhstan 2777 
(2306 to 3283)
15 
(13 to 18)
5·8 
(1·7 to 10·0)
74 482 
(69 375 to 79 913)
419 
(391 to 450)
7·5 
(4·5 to 10·9)
Kyrgyzstan 751 
(625 to 891)
12 
(10 to 15)
–14·3 
(–17·8 to –10·9)
19 731 
(18 264 to 21 228)
354 
(329 to 379)
–6·7 
(–11·4 to –2·0)
Mongolia 496 
(410 to 592)
16 
(13 to 19)
34·1 
(19·4 to 44·4)
12 043 
(11 144 to 12 943)
405 
(377 to 434)
39·1 
(34·1 to 44·5)
Tajikistan 1012 
(836 to 1206)
11 
(9 to 14)
–11·5 
(–15·0 to –8·1)
31 335 
(25 925 to 43 192)
416 
(346 to 568)
20·8 
(2·2 to 63·7)
Turkmenistan 671 
(558 to 792)
12 
(10 to 14)
0·2 
(–3·4 to 3·8)
18 298 
(16 869 to 19 720)
344 
(319 to 369)
8·0 
(4·7 to 11·4)
Uzbekistan 3831 
(3173 to 4538)
12 
(10 to 15)
3·7 
(0·3 to 6·9)
104 924 
(97 144 to 113 211)
355 
(330 to 383)
8·0 
(5·2 to 11·0)
Latin America and Caribbean 44 612 
(36 971 to 53 003)
8 
(7 to 10)
–4·4 
(–8·6 to –1·1)
1 257 730 
(1 167 571 to 1 358 261)
222 
(206 to 239)
1·2 
(–1·1 to 4·3)
Central Latin America 16 957 
(14 048 to 20 273)
7 
(6 to 8)
–14·8 
(–19·8 to –11·6)
481 048 
(439 582 to 529 653)
197 
(181 to 216)
–5·2 
(–7·4 to –2·9)
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Colombia 3224 
(2631 to 3876)
7 
(6 to 8)
–12·6 
(–19·0 to –7·7)
102 906 
(93 911 to 113 136)
210 
(192 to 230)
4·6 
(0·4 to 10·4)
Costa Rica 348 
(285 to 421)
7 
(6 to 9)
16·2 
(12·2 to 20·2)
10 475 
(9631 to 11 355)
209 
(192 to 226)
25·0 
(21·9 to 28·1)
El Salvador 437 
(358 to 528)
7 
(6 to 9)
–22·1 
(–49·3 to –0·6)
16 404 
(11 867 to 27 532)
282 
(202 to 481)
–10·6 
(–22·4 to 4·8)
Guatemala 1134 
(937 to 1355)
7 
(6 to 9)
–3·5 
(–30·6 to 12·3)
28 342 
(24 201 to 36 840)
209 
(177 to 279)
6·4 
(–6·7 to 17·6)
Honduras 511 
(420 to 615)
7 
(6 to 8)
29·8 
(23·4 to 36·7)
14 181 
(12 288 to 16 888)
193 
(168 to 227)
48·5 
(33·4 to 73·7)
Mexico 8221 
(6810 to 9858)
7 
(6 to 8)
–23·8 
(–26·6 to –20·9)
218 025 
(202 252 to 234 802)
177 
(165 to 190)
–17·0 
(–19·5 to –14·2)
Nicaragua 374 
(309 to 449)
6 
(5 to 8)
0·9 
(–4·9 to 5·7)
14 630 
(10 612 to 23 865)
260 
(190 to 421)
–11·3 
(–23·4 to 3·2)
Panama 285 
(234 to 345)
7 
(6 to 9)
14·9 
(10·7 to 18·7)
8224 
(7588 to 8872)
212 
(196 to 228)
21·8 
(18·5 to 24·9)
Venezuela 2424 
(1985 to 2928)
8 
(7 to 10)
11·0 
(6·5 to 16·1)
67 861 
(62 472 to 73 699)
223 
(207 to 242)
20·8 
(16·5 to 27·3)
Andean Latin America 4900 
(4107 to 5740)
8 
(7 to 10)
–2·1 
(–12·2 to 5·5)
134 761 
(124 709 to 147 122)
241 
(224 to 262)
10·6 
(7·7 to 14·3)
Bolivia 858 
(719 to 1002)
8 
(7 to 9)
–9·7 
(–12·8 to –6·6)
21 669 
(19 934 to 23 636)
218 
(202 to 236)
6·5 
(3·8 to 9·4)
Ecuador 1553 
(1249 to 1947)
10 
(8 to 12)
23·9 
(8·7 to 53·4)
36 335 
(33 747 to 39 419)
236 
(220 to 255)
11·6 
(8·2 to 14·4)
Peru 2489 
(2075 to 2913)
8 
(7 to 9)
–11·5 
(–25·3 to –1·5)
76 757 
(70 427 to 84 881)
251 
(231 to 277)
11·3 
(7·1 to 16·6)
Caribbean 3748 
(3111 to 4449)
8 
(7 to 10)
22·1 
(16·4 to 30·7)
120 881 
(99 280 to 156 635)
263 
(216 to 341)
49·7 
(24·2 to 94·0)
Antigua and Barbuda 7  
(6 to 8)
8 
(6 to 9)
11·6 
(8·5 to 15·0)
220 
(203 to 237)
232 
(215 to 250)
15·6 
(12·0 to 19·6)
The Bahamas 30  
(25 to 36)
8 
(7 to 9)
6·6 
(3·2 to 10·0)
906 
(842 to 972)
220 
(204 to 236)
15·7 
(12·2 to 19·3)
Barbados 20  
(16 to 23)
7 
(6 to 8)
16·7 
(14·1 to 19·7)
662 
(616 to 709)
212 
(197 to 228)
20·4 
(16·9 to 25·3)
Belize 28 
(24 to 34)
8 
(7 to 9)
17·2 
(–0·7 to 27·1)
711 
(657 to 770)
212 
(198 to 228)
23·6 
(19·2 to 29·8)
Bermuda 5 
(4 to 6)
8 
(6 to 9)
–2·5 
(–5·7 to 0·9)
174 
(161 to 186)
241 
(223 to 258)
15·7 
(12·3 to 19·4)
Cuba 1054 
(853 to 1310)
9 
(7 to 10)
15·2 
(9·3 to 21·0)
31 067 
(28 803 to 33 423)
236 
(218 to 255)
17·8 
(13·7 to 23·3)
Dominica 5 
(4 to 6)
7 
(6 to 8)
27·6 
(24·2 to 31·1)
158 
(145 to 170)
208 
(192 to 224)
31·1 
(26·0 to 38·3)
Dominican Republic 770 
(636 to 920)
7 
(6 to 9)
26·2 
(22·2 to 30·4)
22 083 
(20 428 to 23 753)
220 
(204 to 236)
33·8 
(29·5 to 40·6)
Grenada 8 
(7 to 10)
8 
(7 to 10)
24·6 
(20·8 to 28·5)
230 
(212 to 248)
220 
(204 to 237)
24·9 
(20·9 to 29·5)
Guyana 59 
(49 to 70)
8 
(7 to 10)
9·5 
(5·7 to 13·4)
1433 
(1336 to 1527)
191 
(179 to 203)
16·6 
(13·2 to 19·9)
Haiti 938 
(747 to 1180)
9 
(7 to 11)
31·2 
(10·5 to 65·2)
37 949 
(18 897 to 72 460)
381 
(188 to 718)
177·3 
(38·9 to 419·8)
Jamaica 194 
(161 to 230)
7 
(6 to 8)
31·0 
(27·0 to 35·2)
5733 
(5309 to 6147)
202 
(187 to 216)
30·1 
(26·0 to 35·4)
Puerto Rico 319 
(260 to 386)
8 
(7 to 10)
22·4 
(17·3 to 27·8)
9695 
(9034 to 10 384)
239 
(222 to 256)
28·9 
(25·2 to 33·2)
Saint Lucia 13 
(11 to 15)
7 
(6 to 9)
16·6 
(13·3 to 19·8)
406 
(378 to 436)
213 
(198 to 228)
24·3 
(21·1 to 28·1)
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Saint Vincent and the Grenadines 9 
(7 to 10)
8 
(7 to 9)
20·4 
(15·8 to 25·1)
242 
(224 to 259)
216 
(201 to 231)
22·0 
(18·6 to 27·7)
Suriname 41 
(35 to 49)
8 
(7 to 9)
20·2 
(16·6 to 24·3)
1180 
(1092 to 1273)
216 
(201 to 233)
21·8 
(15·8 to 26·5)
Trinidad and Tobago 98 
(81 to 118)
8 
(6 to 9)
12·9 
(–1·8 to 21·8)
3186 
(2963 to 3403)
219 
(203 to 234)
31·9 
(28·2 to 37·7)
Virgin Islands 9 
(7 to 10)
8 
(6 to 9)
13·3 
(10·2 to 16·7)
254 
(236 to 273)
217 
(200 to 233)
16·7 
(13·3 to 20·7)
Tropical Latin America 19 006 
(15 547 to 22 905)
9 
(7 to 11)
0·4 
(–4·0 to 5·0)
521 040 
(484 365 to 556 898)
235 
(218 to 251)
–2·4 
(–4·9 to –0·0)
Brazil 18 503 
(15 141 to 22 303)
9 
(7 to 11)
–0·1 
(–4·6 to 4·5)
507 588 
(472 136 to 542 766)
235 
(219 to 252)
–2·9 
(–5·3 to –0·4)
Paraguay 503 
(413 to 606)
8 
(6 to 9)
28·4 
(24·0 to 33·4)
13 452 
(12 233 to 14 741)
216 
(198 to 235)
20·0 
(15·6 to 24·0)
Southeast Asia, east Asia, and 
Oceania 
147 786 
(123 214 to 177 266)
7 
(6 to 9)
8·9 
(–0·1 to 17·5)
5 355 950 
(5 008 161 to 
5 755 826)
234 
(219 to 251)
32·3 
(28·6 to 36·2)
East Asia 101 644 
(84 599 to 122 719)
7 
(6 to 9)
10·0 
(0·2 to 18·6)
3 851 775 
(3 621 176 to 4 082 414)
236 
(222 to 250)
30·7 
(27·4 to 34·0)
China 98 226 
(81 769 to 118 651)
7 
(6 to 9)
9·3 
(–0·5 to 18·1)
3 739 610 
(3 515 973 to 3 963 481)
237 
(223 to 251)
30·6 
(27·3 to 33·9)
North Korea 1767 
(1466 to 2124)
7 
(5 to 8)
44·4 
(33·1 to 59·7)
49 176 
(46 203 to 52 190)
179 
(168 to 190)
35·0 
(31·8 to 38·6)
Taiwan (province of China) 1650 
(1368 to 1999)
7 
(6 to 9)
21·6 
(14·7 to 29·9)
62 989 
(59 405 to 66 948)
227 
(213 to 242)
29·3 
(25·6 to 33·7)
Southeast Asia 45 349 
(38 407 to 54 280)
7 
(6 to 8)
6·4 
(–11·2 to 18·2)
1 486 699 
(1 324 441 to 1 766 643)
228 
(204 to 271)
37·3 
(26·7 to 47·9)
Cambodia 1020 
(860 to 1206)
7 
(6 to 8)
–13·9 
(–47·8 to 17·1)
49 783 
(29 731 to 102 600)
377 
(212 to 820)
–15·9 
(–29·5 to 17·0)
Indonesia 16 383 
(13 827 to 19 498)
7 
(6 to 8)
14·1 
(8·9 to 19·3)
525 421 
(479 338 to 584 463)
205 
(188 to 229)
33·2 
(21·5 to 44·5)
Laos 444 
(377 to 528)
6 
(5 to 7)
–26·8 
(–60·8 to 11·5)
10 096 
(9319 to 10 871)
164 
(153 to 177)
48·7 
(42·8 to 53·3)
Malaysia 2304 
(1920 to 2798)
8 
(6 to 9)
23·2 
(18·0 to 29·5)
70 211 
(66 032 to 74 696)
229 
(216 to 243)
33·2 
(30·6 to 35·7)
Maldives 20 
(17 to 23)
6 
(5 to 6)
–0·8 
(–4·6 to 3·1)
632 
(585 to 678)
184 
(171 to 196)
30·9 
(27·0 to 35·4)
Mauritius 81 
(68 to 96)
7 
(6 to 8)
30·3 
(25·0 to 36·4)
2866 
(2698 to 3052)
206 
(194 to 220)
41·9 
(38·7 to 46·3)
Myanmar 3367 
(2848 to 3916)
6 
(5 to 7)
25·6 
(14·7 to 34·3)
137 785 
(109 122 to 183 939)
256 
(203 to 343)
69·4 
(31·5 to 124·7)
Philippines 7921 
(6314 to 10 612)
8 
(6 to 10)
7·5 
(–10·6 to 24·8)
204 930 
(178 886 to 256 102)
219 
(190 to 279)
28·6 
(12·3 to 39·8)
Sri Lanka 1593 
(1350 to 1885)
8 
(7 to 9)
–63·7 
(–84·1 to –23·6)
94 402 
(61 940 to 170 102)
435 
(286 to 783)
93·5 
(48·8 to 161·0)
Seychelles 8 
(6 to 9)
8 
(7 to 9)
24·9 
(20·1 to 31·0)
225 
(211 to 240)
223 
(209 to 237)
35·5 
(28·2 to 40·3)
Thailand 5507 
(4550 to 6744)
8 
(7 to 10)
16·5 
(11·1 to 22·3)
186 063 
(175 707 to 197 225)
239 
(226 to 254)
29·4 
(26·3 to 33·2)
Timor-Leste 69 
(59 to 81)
6 
(5 to 7)
–70·0 
(–88·0 to –25·0)
5688 
(2514 to 13 572)
677 
(280 to 1658)
41·3 
(21·3 to 65·7)
Vietnam 6571 
(5510 to 7844)
7 
(6 to 8)
36·7 
(30·7 to 43·2)
196 504 
(184 525 to 208 822)
204 
(192 to 217)
52·0 
(48·1 to 55·7)
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Oceania 793 
(672 to 941)
7 
(6 to 9)
12·5 
(–1·5 to 21·8)
17 477 
(16 227 to 18 776)
172 
(160 to 184)
39·6 
(35·0 to 46·2)
American Samoa 6 
(5 to 7)
8 
(7 to 9)
6·2 
(2·5 to 10·0)
172 
(159 to 186)
229 
(214 to 247)
19·9 
(14·8 to 28·4)
Federated States of Micronesia 7 
(6 to 8)
7 
(6 to 8)
19·2 
(15·2 to 24·0)
161 
(150 to 172)
170 
(160 to 181)
27·6 
(23·6 to 32·7)
Fiji 56 
(47 to 66)
7 
(6 to 8)
29·3 
(24·6 to 35·0)
1533 
(1431 to 1641)
174 
(163 to 186)
36·8 
(34·1 to 39·5)
Guam 14 
(12 to 17)
8 
(7 to 10)
24·7 
(20·1 to 29·9)
409 
(384 to 434)
233 
(219 to 248)
27·8 
(23·9 to 33·0)
Kiribati 7 
(6 to 9)
6 
(5 to 8)
32·5 
(27·6 to 37·7)
160 
(148 to 174)
152 
(141 to 167)
50·0 
(43·8 to 63·0)
Marshall Islands 5 
(4 to 6)
7 
(6 to 8)
21·3 
(16·8 to 26·6)
108 
(101 to 116)
160 
(150 to 170)
20·7 
(18·0 to 23·3)
Northern Mariana Islands 10 
(8 to 12)
8 
(7 to 10)
6·8 
(3·9 to 10·1)
288 
(268 to 309)
237 
(224 to 253)
8·5 
(6·1 to 11·9)
Papua New Guinea 562 
(476 to 669)
7 
(6 to 9)
8·1 
(–9·5 to 19·7)
11 718 
(10 834 to 12 664)
168 
(156 to 181)
44·9 
(38·9 to 54·0)
Samoa 14 
(11 to 16)
7 
(6 to 8)
18·4 
(14·3 to 23·1)
344 
(318 to 377)
199 
(185 to 217)
36·1 
(30·0 to 45·9)
Solomon Islands 41 
(34 to 48)
7 
(6 to 8)
22·3 
(17·7 to 28·0)
856 
(794 to 919)
164 
(153 to 175)
30·9 
(27·7 to 34·0)
Tonga 7 
(6 to 9)
7 
(6 to 8)
14·1 
(8·8 to 19·7)
175 
(163 to 186)
184 
(173 to 195)
24·5 
(22·0 to 27·1)
Vanuatu 19 
(16 to 22)
7 
(6 to 8)
27·2 
(22·1 to 33·1)
406 
(374 to 444)
166 
(153 to 182)
38·2 
(34·0 to 43·7)
North Africa and Middle East 114 545 
(60 192 to 250 395)
19 
(10 to 40)
69·6 
(1·2 to 219·0)
2 419 341 
(1 598 927 to 
4 560 625)
447 
(298 to 843)
4·1 
(–3·2 to 13·1)
Afghanistan 14 304 
(4044 to 38 406)
37 
(11 to 101)
167·8 
(–1·1 to 410·1)
313 721 
(101 502 to 865 339)
1367 
(392 to 3875)
–15·7 
(–26·0 to 35·3)
Algeria 3284 
(2785 to 3845)
8 
(7 to 10)
–5·4 
(–7·9 to –2·7)
106 241 
(96 415 to 124 577)
276 
(252 to 319)
12·5 
(5·3 to 28·7)
Bahrain 122 
(104 to 145)
9 
(8 to 11)
–3·9 
(–8·5 to –0·1)
4500 
(4186 to 4828)
309 
(289 to 331)
13·1 
(9·8 to 16·9)
Egypt 7493 
(6276 to 9128)
8 
(7 to 10)
24·4 
(16·5 to 43·7)
201 767 
(184 848 to 225 697)
234 
(215 to 263)
24·0 
(19·9 to 29·4)
Iran 7332 
(6167 to 8763)
9 
(8 to 11)
–56·2 
(–76·0 to –21·2)
388 904 
(258 799 to 723 827)
482 
(322 to 896)
–17·4 
(–26·8 to –3·6)
Iraq 16 663 
(5613 to 47 047)
37 
(13 to 105)
236·9 
(25·5 to 701·4)
388 270 
(147 340 to 1 027 960)
1331 
(498 to 3581)
–7·7 
(–19·3 to 14·3)
Jordan 1204 
(663 to 2460)
14 
(8 to 30)
68·3 
(–2·7 to 246·7)
16 977 
(15 689 to 18 348)
247 
(230 to 265)
–2·5 
(–6·0 to 2·6)
Kuwait 365 
(308 to 429)
10 
(8 to 11)
–64·1 
(–86·5 to –18·1)
13 897 
(12 640 to 16 107)
342 
(314 to 386)
5·9 
(2·0 to 13·5)
Lebanon 669 
(449 to 1195)
12 
(8 to 21)
–67·9 
(–82·0 to –39·3)
91 954 
(33 043 to 252 384)
1590 
(567 to 4363)
–26·3 
(–31·9 to –13·0)
Libya 1269 
(585 to 3231)
20 
(10 to 51)
146·1 
(19·9 to 512·5)
36 616 
(19 378 to 78 295)
571 
(313 to 1208)
89·7 
(14·6 to 237·8)
Morocco 2466 
(2084 to 2896)
7 
(6 to 9)
–1·6 
(–7·0 to 1·9)
82 368 
(76 645 to 88 686)
242 
(226 to 261)
9·8 
(5·9 to 13·2)
Oman 461 
(381 to 559)
10 
(8 to 12)
–3·3 
(–7·0 to 0·1)
14 520 
(13 596 to 15 636)
312 
(293 to 335)
5·3 
(2·6 to 8·2)
Palestine 504 
(400 to 668)
9 
(7 to 11)
–24·3 
(–53·6 to 7·5) 
21 989 
(11 872 to 48 698)
613 
(304 to 1432) 
–13·0 
(–22·5 to 8·9) 
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Qatar 265 
(219 to 320)
11 
(10 to 14)
–3·5 
(–6·1 to –0·8)
8857 
(8206 to 9463)
375 
(351 to 399)
3·3 
(0·9 to 5·8)
Saudi Arabia 2948 
(2498 to 3469)
9 
(8 to 11)
–13·6 
(–16·2 to –10·9)
89 085 
(83 584 to 94 849)
291 
(274 to 308)
–8·2 
(–10·2 to –5·7)
Sudan 4274 
(3005 to 6775)
10 
(7 to 16)
8·0 
(–13·6 to 31·9)
103 888 
(78 840 to 166 051)
298 
(227 to 477)
27·4 
(20·2 to 39·1)
Syria 27 672 
(5097 to 90 873)
136 
(25 to 441)
1878·0 
(264·0 to 6479·8)
159 497 
(64 351 to 401 256)
839 
(367 to 2049)
228·8 
(71·6 to 485·6)
Tunisia 966 
(809 to 1173)
9 
(7 to 11)
9·1 
(2·4 to 25·4)
31 176 
(28 902 to 33 771)
268 
(249 to 290)
13·7 
(10·0 to 17·9)
Turkey 7321 
(5931 to 9464)
9 
(8 to 12)
–6·6 
(–16·3 to 15·1)
231 112 
(212 709 to 258 146)
288 
(265 to 321)
–1·8 
(–7·6 to 9·1)
United Arab Emirates 1051 
(870 to 1261)
11 
(9 to 13)
–6·8 
(–8·9 to –4·6)
35 473 
(33 003 to 37 961)
337 
(315 to 360)
–3·1 
(–5·8 to –0·3)
Yemen 13 802 
(4761 to 37 003)
42 
(15 to 111)
408·7 
(84·9 to 1 265·1)
75 800 
(55 113 to 129 308)
314 
(235 to 509)
20·1 
(8·0 to 38·6)
South Asia 180 120 
(151 167 to 213 759)
11 
(10 to 13)
–2·1 
(–5·9 to 1·5)
4 127 359 
(3 895 776 to 
4 387 308)
256 
(242 to 272)
20·3 
(18·3 to 22·7)
Bangladesh 14 525 
(12 236 to 17 308)
9 
(8 to 11)
5·9 
(1·6 to 10·5)
368 288 
(340 422 to 405 978)
244 
(226 to 270)
35·7 
(29·9 to 44·2)
Bhutan 81 
(68 to 96)
11 
(9 to 13)
0·3 
(–2·4 to 3·0)
2043 
(1913 to 2192)
276 
(259 to 295)
26·6 
(23·0 to 31·1)
India 143 743 
(120 391 to 170 991)
12 
(10 to 14)
–4·2 
(–8·4 to –0·4)
3 252 768 
(3 074 402 to 3 448 115)
257 
(243 to 272)
17·5 
(16·0 to 19·0)
Nepal 2870 
(2421 to 3380)
10 
(8 to 12)
0·1 
(–3·0 to 3·6)
69 217 
(62 575 to 78 982)
260 
(236 to 293)
38·9 
(29·9 to 56·2)
Pakistan 18 902 
(16 015 to 22 050)
10 
(9 to 12)
14·1 
(10·3 to 18·3)
435 044 
(402 203 to 472 539)
255 
(237 to 274)
30·0 
(24·4 to 38·7)
Sub-Saharan Africa 82 830 
(70 088 to 98 128)
9 
(7 to 10)
–30·4 
(–52·9 to –12·0)
1 811 159 
(1 537 081 to 2 405 237)
232 
(194 to 319)
12·6 
(6·2 to 24·2)
Southern sub-Saharan Africa 6185 
(5194 to 7421)
8 
(7 to 10)
–21·0 
(–36·3 to –12·2)
140 222 
(130 205 to 151 679)
191 
(178 to 209)
–13·5 
(–15·7 to –11·1)
Botswana 190 
(158 to 227)
9 
(7 to 10)
12·6 
(9·2 to 16·6)
4289 
(4000 to 4585)
195 
(183 to 206)
8·7 
(6·7 to 10·8)
eSwatini 113 
(94 to 135)
9 
(7 to 10)
13·2 
(9·9 to 16·6)
1963 
(1826 to 2104)
163 
(153 to 173)
–6·5 
(–8·3 to –4·6)
Lesotho 171 
(143 to 203)
8 
(7 to 10)
18·4 
(13·9 to 22·6)
2796 
(2594 to 2995)
132 
(125 to 141)
–10·6 
(–12·9 to –7·8)
Namibia 185 
(155 to 219)
7 
(6 to 9)
0·4 
(–1·8 to 2·5)
3987 
(3697 to 4282)
175 
(163 to 186)
5·5 
(3·2 to 8·0)
South Africa 4444 
(3702 to 5367)
9 
(7 to 10)
–26·5 
(–42·9 to –16·0)
107 631 
(99 619 to 118 234)
206 
(191 to 228)
–16·4 
(–18·9 to –13·6)
Zimbabwe 1084 
(920 to 1267)
7 
(6 to 8)
2·9 
(–0·4 to 5·7)
19 556 
(18 025 to 21 070)
140 
(131 to 149)
0·4 
(–1·2 to 2·0)
Western sub-Saharan Africa 33 433 
(28 312 to 39 509)
9 
(7 to 10)
–6·7 
(–14·1 to –2·5)
648 235 
(588 267 to 723 553)
202 
(186 to 226)
10·1 
(6·0 to 19·1)
Benin 906 
(768 to 1067)
9 
(7 to 10)
1·8 
(–0·9 to 4·6)
17 000 
(15 734 to 18 325)
187 
(175 to 200)
5·4 
(3·1 to 7·6)
Burkina Faso 1512 
(1275 to 1779)
9 
(7 to 10)
–2·6 
(–5·6 to 1·3)
26 537 
(24 449 to 28 527)
179 
(167 to 190)
11·1 
(8·6 to 13·2)
Cameroon 2059 
(1721 to 2448)
9 
(7 to 11)
6·1 
(0·9 to 17·1)
36 183 
(33 240 to 39 021)
179 
(166 to 192)
–1·5 
(–4·2 to 1·9)
Cape Verde 45 
(38 to 52)
8 
(7 to 10)
9·4 
(6·1 to 12·8)
1109 
(1029 to 1189)
225 
(210 to 239)
16·6 
(14·2 to 19·1)
(Table 2 continues on next page)
Articles
74 www.thelancet.com/neurology   Vol 18   January 2019
Incidence Prevalence
2016 counts 2016 
age-standardised rates 
(per 100 000)
Percentage change 
in age-standardised 
rates, 1990–2016
2016 counts 2016 age-standardised 
rates (per 100 000)
Percentage change in 
age-standardised rates, 
1990–2016
(Continued from previous page)
Chad 1227 
(1038 to 1437)
9 
(7 to 10)
–32·0 
(–61·0 to –2·6)
25 952 
(21 330 to 35 887)
247 
(194 to 368)
1·3 
(–5·7 to 7·2)
Côte d’Ivoire 1968 
(1668 to 2297)
9 
(8 to 11)
–4·6 
(–7·1 to –1·9)
36 366 
(33 388 to 39 550)
186 
(173 to 201)
1·7 
(–1·2 to 6·8)
The Gambia 157 
(132 to 184)
8 
(7 to 9)
–8·2 
(–10·1 to –6·3)
3081 
(2800 to 3417)
196 
(179 to 226)
–6·7 
(–11·9 to –3·2)
Ghana 2301 
(1953 to 2690)
9 
(7 to 10)
10·5 
(8·0 to 13·0)
46 645 
(43 313 to 50 073)
196 
(183 to 209)
19·4 
(15·9 to 23·3)
Guinea 973 
(822 to 1 133)
8 
(7 to 9)
–6·8 
(–9·1 to –4·4)
18 154 
(16 817 to 19 621)
170 
(159 to 183)
–5·5 
(–8·5 to –1·0)
Guinea-Bissau 157 
(132 to 183)
9 
(7 to 10)
–8·5 
(–10·4 to –6·7)
2896 
(2629 to 3280)
177 
(162 to 202)
4·0 
(–2·2 to 18·3)
Liberia 324 
(275 to 379)
7 
(6 to 9)
–85·7 
(–94·6 to –59·7)
12 285 
(7581 to 24 974)
339 
(203 to 698)
77·5 
(15·8 to 189·6)
Mali 1427 
(1206 to 1699)
8 
(7 to 10)
–12·4 
(–23·3 to –5·9)
28 992 
(24 231 to 39 739)
211 
(176 to 292)
29·0 
(10·1 to 77·9)
Mauritania 326 
(275 to 382)
9 
(7 to 10)
–31·1 
(–59·6 to –7·6)
7511 
(6963 to 8060)
220 
(205 to 235)
14·2 
(12·0 to 16·6)
Niger 1545 
(1308 to 1825)
8 
(7 to 9)
–15·3 
(–24·7 to –9·5)
25 726 
(23 640 to 27 889)
169 
(157 to 182)
–2·5 
(–5·1 to 1·0)
Nigeria 16 220 
(13 543 to 19 530)
9 
(8 to 11)
3·0 
(–2·7 to 16·5)
311 002 
(284 603 to 338 096)
210 
(194 to 227)
11·0 
(7·2 to 17·3)
São Tomé and Príncipe 18 
(15 to 21)
9 
(8 to 11)
4·0 
(1·4 to 6·5)
363 
(336 to 389)
231 
(216 to 246)
7·7 
(5·4 to 10·1)
Senegal 1215 
(1027 to 1417)
8 
(7 to 10)
–3·2 
(–8·5 to 0·4)
23 803 
(21 961 to 25 655)
191 
(178 to 205)
5·4 
(2·3 to 9·7)
Sierra Leone 498 
(421 to 582)
8 
(7 to 10)
–5·2 
(–7·4 to –2·9)
13 960 
(10 075 to 23 417)
263 
(188 to 451)
51·0 
(7·2 to 154·5)
Togo 555 
(468 to 649)
8 
(7 to 9)
–2·3 
(–4·9 to 0·2)
10 662 
(9872 to 11 516)
170 
(159 to 182)
–1·6 
(–4·1 to 1·9)
Eastern sub-Saharan Africa 33 178 
(27 991 to 39 389)
9 
(8 to 11)
–48·2 
(–71·0 to –20·4)
804 687 
(624 381 to 1 220 333)
274 
(206 to 441)
20·4 
(13·0 to 33·0)
Burundi 1045 
(878 to 1240)
10 
(8 to 11)
3·1 
(–0·6 to 10·1)
27 356 
(19 445 to 46 950)
311 
(216 to 553)
108·2 
(43·3 to 268·0)
Comoros 63 
(53 to 75)
9 
(7 to 10)
–20·3 
(–22·5 to –18·1)
1394 
(1295 to 1495)
212 
(199 to 226)
10·7 
(7·7 to 14·9)
Djibouti 87 
(73 to 102)
9 
(8 to 11)
–24·4 
(–47·3 to –8·7)
1908 
(1754 to 2107)
230 
(212 to 255)
2·8 
(–1·9 to 12·1)
Eritrea 454 
(383 to 532)
9 
(8 to 11)
–3·4 
(–6·2 to –0·4)
13 098 
(9461 to 21 689)
301 
(217 to 506)
80·4 
(29·8 to 197·0)
Ethiopia 8607 
(7299 to 10 139)
9 
(8 to 11)
–75·0 
(–88·9 to –44·2)
223 360 
(172 265 to 347 531)
287 
(213 to 474)
13·0 
(6·0 to 19·5)
Kenya 3977 
(3363 to 4640)
9 
(8 to 11)
7·3 
(5·9 to 8·7)
83 265 
(77 387 to 89 234)
215 
(201 to 228)
17·2 
(15·4 to 19·8)
Madagascar 1943 
(1630 to 2280)
8 
(7 to 10)
–5·0 
(–7·7 to –2·0)
36 761 
(33 937 to 39 548)
178 
(166 to 190)
2·4 
(–0·3 to 5·5)
Malawi 1280 
(1080 to 1504)
7 
(6 to 9)
–13·4 
(–15·8 to –10·9)
21 452 
(19 639 to 23 177)
146 
(136 to 156)
–4·7 
(–7·5 to –1·7)
Mozambique 2341 
(1972 to 2747)
9 
(7 to 10)
–24·0 
(–53·9 to 0·4)
60 152 
(41 299 to 106 716)
308 
(188 to 595)
–18·8 
(–29·7 to 0·3)
Rwanda 908 
(761 to 1067)
8 
(7 to 9)
–58·4 
(–79·8 to –30·3)
85 439 
(32 287 to 224 253)
931 
(346 to 2464)
453·5 
(106·2 to 1 244·1)
Somalia 1709 
(985 to 3437)
16 
(10 to 31)
–21·3 
(–28·7 to –11·7)
27 548 
(17 750 to 53 134)
329 
(209 to 637)
33·3 
(6·7 to 71·9)
(Table 2 continues on next page)
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injury—ie, these conditions previously had been measured 
as consequences of causes of injury. For example, a cause, 
such as a fall, could lead to SCI. Historically falls have been 
measured and reported but the actual nature of injury 
(eg, TBI, ankle fracture) that occurred because of the fall 
has not been directly reported. This aspect of the GBD 
study design was consistent across other natures of 
injuries. Second, estimation of TBI and SCI deviated from 
the GBD study framework in terms of the measures that 
were reported for the conditions, because we do not 
estimate death from TBI or SCI. Although TBI and SCI 
can lead to death, they were not considered causes of death 
in the GBD 2016 framework. Instead, the cause of injury 
(eg, falls) that led to a nature of injury such as TBI was 
considered the cause of death. For example, an individual 
who had a fall, sustained a TBI, and then died while in 
hospital after the injury would be considered to have had a 
death caused by a fall and an incident TBI. In this study, 
we estimated the non-fatal burden and therefore report 
incidence, pre valence, and YLDs, but not cause-specific 
mortality or years of life lost.
Cause-of-injury estimation
The process for estimation of incidence, prevalence, 
and YLDs was as follows. First, the incidence of 29 dif -
ferent causes of injury (appendix 1) were modelled 
with DisMod-MR 2.1, a meta-regression tool that was 
used extensively throughout the GBD study.3 These 
cause-of-injury models measured the incidence of each 
cause of injury that required medical care, which included 
patients who were admitted or seen in an outpatient clinic 
and received a diagnosis code for a given cause of injury. 
Receiving an injury diagnosis code did not preclude the 
possibility of death in the hospital or after discharge. Each 
of these cause models used an array of data types, including 
surveillance studies, literature studies, hospital discharge 
records, and emergency de partment records. The details of 
these models have previously been described in more 
detail.3 Although we do not estimate death from TBI or 
SCI in this study, our modelling strategy also included 
cause-specific mortality rates from the cause of death 
ensemble model to inform incidence estimates for cause-
of-injury models such as road injuries in data-sparse areas 
using estimates from data-rich areas.18 The outputs from 
these models were estimates of inpatient (admitted) and 
outpatient incidence rates of causes of injury and were 
specific for location, sex, age, and year. The outpatient 
incidence of each cause was derived from the inpatient 
incidence on the basis of a regression coefficient for 
outpatient incidence that was extracted from DisMod-MR 
2.1 incidence models in locations that had both inpatient 
and outpatient data.
Nature-of-injury estimation
Clinical record data that coded for both cause and nature of 
injury were used to estimate the proportion of each cause 
Incidence Prevalence
2016 counts 2016 
age-standardised rates 
(per 100 000)
Percentage change 
in age-standardised 
rates, 1990–2016
2016 counts 2016 age-standardised 
rates (per 100 000)
Percentage change in 
age-standardised rates, 
1990–2016
(Continued from previous page)
South Sudan 1455 
(1158 to 1935)
11 
(9 to 14)
–59·4 
(–79·6 to –21·2)
36 330 
(23 858 to 66 348)
358 
(230 to 667)
35·6 
(2·6 to 87·0)
Tanzania 4584 
(3883 to 5363)
9 
(7 to 10)
–4·2 
(–6·3 to –2·1)
84 663 
(78 171 to 91 074)
192 
(179 to 205)
6·8 
(4·5 to 9·2)
Uganda 3215 
(2700 to 3747)
8 
(7 to 10)
–11·7 
(–29·0 to –1·6)
76 806 
(57 559 to 123 332)
292 
(192 to 540)
–7·5 
(–24·3 to 23·6)
Zambia 1487 
(1252 to 1747)
10 
(8 to 11)
2·5 
(–2·1 to 5·9)
24 612 
(22 713 to 26 463)
180 
(168 to 192)
2·7 
(0·3 to 4·8)
Central sub-Saharan Africa 10 034 
(8473 to 11 871)
9 
(8 to 11)
–14·3 
(–29·1 to –5·7)
218 015 
(177 254 to 313 214)
243 
(194 to 357)
22·1 
(11·0 to 42·6)
Angola 2361 
(1989 to 2757)
10 
(8 to 11)
–38·2 
(–66·2 to –9·8)
59 309 
(44 235 to 95 957)
339 
(234 to 593)
5·2 
(–9·3 to 23·8)
Central African Republic 434 
(348 to 551)
9 
(7 to 11)
14·8 
(3·2 to 42·3)
8061 
(6335 to 12 014)
171 
(137 to 247)
32·9 
(7·6 to 93·0)
Congo (Brazzaville) 426 
(360 to 508)
9 
(8 to 11)
–0·5 
(–3·8 to 5·8)
11 542 
(8420 to 19 317)
302 
(218 to 516)
81·9 
(31·0 to 207·4)
Democratic Republic of the 
Congo
6569 
(5542 to 7777)
9 
(7 to 10)
–4·5 
(–7·3 to –0·3)
133 941 
(112 213 to 181 770)
216 
(181 to 296)
27·6 
(8·5 to 74·1)
Equatorial Guinea 81 
(68 to 94)
10 
(9 to 12)
11·8 
(6·6 to 16·5)
1697 
(1584 to 1805)
234 
(219 to 247)
53·4 
(49·7 to 57·2)
Gabon 163 
(138 to 191)
10 
(8 to 11)
–10·9 
(–12·9 to –8·9)
3464 
(3219 to 3720)
225 
(211 to 240)
3·6 
(1·6 to 5·7)
95% uncertainty intervals are in parentheses. SDI=Socio-demographic Index.
Table 2: Incidence and prevalence of spinal cord injury in 2016, and percentage change in age-standardised rates by location, 1990–2016
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that resulted in each nature of injury. If an injury cause 
resulted in more than one nature of injury, the most severe 
was chosen on the basis of a mixed-effects regression 
model that estimated the disability ex perienced by an 
injured individual adjusted for age, sex, and never-injured 
status, with country and individual random effects. 
Because SCI was associated with higher disability than 
TBI (appendix 1), SCI was chosen if both conditions 
occurred as a result of the same injury. We used this 
method after finding in a previous GBD study19 that 
statistically assigning multiple injury categories to a single 
individual was difficult because of a sparsity of data. This 
process and the severity rankings are de scribed in more 
detail in appendix 1. These proportions were calculated for 
each external cause-of-injury–nature-of-injury (cause–
nature) combination, such that the proportions of all 
natures of injury for a given cause of injury sum to 1 
because of a Dirichlet regression. The output from this 
step was incidence for each cause–nature combination.
Derivation of incidence, prevalence, and YLDs
From the incidence estimates for each cause–nature 
combination, we separately modelled short-term and long-
term estimates using proportions of individuals expected 
to experience short-term versus long-term disability (the 
cutoff for long-term disability was 1 year). The proportions 
estimated to experience permanent health loss generally 
increased with age and were different for TBI and SCI 
(appendix 1). The short-term prevalence estimates were 
then calculated on the basis of average duration of a short-
term case, whereas the long-term estimates were con-
sidered to be permanent and underwent comorbidity 
adjustment as described pre viously.3 Cause–nature in-
cidence rates were converted to prevalence with the 
differential equation solver used in DisMod-MR 2.1. This 
solver reconciled the incidence rates from the previous 
steps with standardised mortality ratios derived from 
literature studies to estimate prevalence, because people 
with long-term disability due to TBI and SCI die at a higher 
rate than the background mortality in the population.20 The 
final output from this step was prevalence of each cause–
nature combination for each location, year, age, and sex 
combination.
YLDs were then calculated by multiplying the pre-
valence by the disability weight. Measurement has been 
described in more detail previously, but in summary, 
disability weights were measured through population and 
internet surveys on the basis of lay descriptions of 
disabling conditions.21 For example, the disability weight 
for short-term mild TBI and for short-term moderate 
or severe TBI were 0·110 (95% uncertainty interval 
[UI] 0·074–0·158) and 0·214 (0·141–0·297), respectively, 
Figure 1: Age-standardised incidence of traumatic brain injury per 100 000 population by location for both sexes, 2016
ATG=Antigua and Barbuda. FSM=Federated States of Micronesia. Isl=Islands. LCA=Saint Lucia. TLS=Timor-Leste. TTO=Trinidad and Tobago. VCT=Saint Vincent and the Grenadines. 
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meaning that the affected people experienced health 
losses of 11·0% and 21·4%, respectively, compared with a 
person in full health. All disability weights for different 
severities of TBI and SCI are provided in appendix 1.
After estimation of YLDs, the prevalence, incidence, 
and YLDs for TBI and SCI were then summed across all 
causes to estimate the all-injury prevalence, incidence, 
and YLDs for TBI and SCI separately. Uncertainty was 
propagated throughout this process by maintaining 
distributions of 1000 draws for each estimation stage 
(including percentage change over time). We use the 
25th and 975th sorted values in the draw distributions as 
the upper and lower UIs for mean estimates and for 
percentage change, whereby change was judged to be 
significant if the lower and upper UIs did not overlap 
zero. This process is consistent with management of 
uncertainty throughout the GBD study framework.3
Statistical analysis
We grouped countries into quintiles on the basis of their 
2016 Socio-demographic Index (SDI) value, which is a 
composite measure of development derived from income 
per person, educational attainment, and total fertility rate.17 
Additionally, we measured the most common causes of 
TBI and SCI separately in terms of the original cause of 
injury that led to the disability. Finally, we measured the 
proportion of TBI that was mild versus the proportion that 
was moderate or severe and the proportion of SCI that 
occurred at the neck versus below the neck and present 
these values at the global level. Analyses were done 
in Python (version 2.7), Stata (version 13.1), and 
R (version 3.3). Statistical code used for this study will be 
made available upon publication of this Article via the 
Institute for Health Metrics and Evaluation. This study 
complies with the Guidelines for Accurate and Transparent 
Health Estimates Report (GATHER) recommendations 
(appendix 1).
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or the writing 
of the report. All authors had full access to the data in the 
study and had final responsibility for the decision to 
submit for publication.
Results
We used incidence data for every cause of injury and every 
GBD region. The number of sources by injury and by 
region are in appendix 1. Incidence, prevalence, and YLD 
estimates for every cause of injury by age, sex, and 
location for 1990–2016 are available through an online 
results tool.
Figure 2: Age-standardised incidence of spinal cord injury per 100 000 population by location for both sexes, 2016
ATG=Antigua and Barbuda. FSM=Federated States of Micronesia. Isl=Islands. LCA=Saint Lucia. TLS=Timor-Leste. TTO=Trinidad and Tobago. VCT=Saint Vincent and the Grenadines.
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For the online results tool see 
http://ghdx.healthdata.org/gbd-
results-tool
For the statistical code used for 
this study see http://healthdata.
org
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Table 1 shows the incidence and prevalence of TBI in 
terms of all-age counts, age-standardised rates (per 
100 000 population), and percentage change in age-
standardised rates between 1990 and 2016. Table 2 shows 
the same information for SCI. YLDs from TBI and SCI in 
terms of all-age counts, age-standardised rates, and total 
percentage change are in appendix 2, which also includes 
these estimates by age and sex, and for 1990. Between 
1990 and 2016, age-standardised incidence rates signi-
ficantly increased by 3·6% (95% UI 1·8 to 5·5) for TBI 
and decreased non-significantly by –3·6% (–7·4 to 4·0) for 
SCI, leading to age-standardised incidence rates of 
369 (331 to 412) per 100 000 for TBI and 13 (11 to 16) per 
100 000 for SCI (tables 1, 2).
Figures 1 and 2 show the age-standardised incidence by 
country for 2016 for TBI and SCI, respectively. Central 
Europe, eastern Europe, and central Asia had substantially 
higher incidence rates of TBI than the rest of the world; at 
the regional level, the age-standardised incidence rate was 
highest in central Europe, at 857 (95% UI 750–988) per 
100 000 (table 1). Syria had the highest age-standardised 
incidence rate of TBI of any country, with 1322 (95% UI 
481–2779) cases per 100 000. Slovenia (1092 [938–1294] per 
100 000) and the Czech Republic (1022 [885–1191] per 
100 000) had the next highest age-standardised incidence 
rates. The incidence rates for SCI were highest in the 
high SDI regions high-income North America (26 [20–33] 
per 100 000) and Western Europe (26 [20–33] per 100 000; 
table 2). However, at a country level, Syria had the highest 
age-standardised incidence rate of SCI (136 [25–441] per 
100 000), followed by Yemen (42 [15–111] per 100 000), Iraq 
(37 [13–105] per 100 000), and Afghanistan (37 [11–101]; 
table 2).
In terms of individuals living with disability from these 
conditions in 2016, TBI had a global age-standardised 
prevalence of 759 (95% UI 731–788) per 100 000 (table 1), 
and SCI had a global age-standardised prevalence of 
368 (340–409) per 100 000 (table 2). These estimates 
corresponded to 55 million (53–58) individuals with TBI 
and 27 million (25–30) with SCI (for unrounded estimates 
see table 1). From 1990 to 2016, the age-standardised 
prevalence of TBI increased by 8·4% (95% UI 7·7 to 9·2; 
table 1), whereas that of SCI decreased non-significantly by 
–0·2% (–2·1 to 2·7; table 2). Age-standardised prevalence 
of TBI was high in the super-region of cental Europe, 
eastern Europe, and central Asia at 1539 (1464–1614) per 
100 000, representing roughly 7·5 million prevalent cases 
(7·1–7·9). Age-standardised prevalence for SCI was 
highest in high SDI regions—specifically western Europe 
(854 [780–945 per 100 000) and high-income Asia Pacific 
(821 [747–907] per 100 000; table 2).
TBI and SCI caused 8·1 million (95% UI 6·0–10·4) and 
9·5 million (6·7–12·4) YLDs, respectively, in 2016. The age-
standardised YLD rates were 111 (82–141) per 100 000 for 
TBI and 130 (90–170) per 100 000 for SCI (appendix 2). The 
global age-standardised YLD rates per 100 000 population 
for TBI increased by 8·5% (7·6–9·3) from 1990 to 2016 
and those for SCI decreased by 10·0% (7·0–13·3) from 
1990 to 2016. At the country level, for TBI, the distribution 
of YLDs was similar to those of incidence and prevalence. 
Specifically, countries in central Europe, eastern Europe, 
and central Asia had the highest age-standardised YLD 
rates, with country-specific rates ranging from 135 (99–175) 
per 100 000 in Tajikistan to 335 (241–421) per 100 000 in 
Slovenia. For SCI, the high-income super-region had the 
highest age-standardised YLD rates (229 [159–303] per 
100 000). Within these locations, Finland (287 [197–381] per 
100 000), Ireland (283 [192–373] per 100 000), and Israel (282 
[181–396] per 100 000) had the highest age-standardised 
YLD rates.
Figure 3 shows the global age-specific and sex-specific 
incidence rates per 100 000 for minor TBI, moderate or 
severe TBI, spinal cord lesions at the neck, and spinal cord 
lesions below the neck for 2016. For TBI, these figures 
show divergent patterns between males and females that 
start in teenage years and extend to ages 50–60 years 
(figure 3). At older ages (ie, older than 60 years), the sex-
specific incidence rates in males and females is similar 
(figure 3). The incidence is more similar between the 
sexes for both subtypes of SCI than for TBI, although men 
have higher incidences than women of spinal cord lesions 
at the neck level at ages 20–40 years (figure 3).
Figure 3: Global incidence of minor (A) and moderate or severe (B) traumatic brain injury, and of spinal cord 
injury at neck level (C) and below neck level (D), by age and sex, 2016
Shaded regions represent 95% uncertainty intervals.
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The proportion of causes leading to TBI and SCI by 
region are shown in figure 4. In general, falls were the 
main cause of TBI. In some regions, such as central 
Europe, more than 50% of the age-standardised incidence 
of TBI was caused by falls; in other regions, such as 
Oceania, falls were still the predominant cause but 
accounted for a smaller proportion of the age-standardised 
incidence (figure 4). In addition to having high age-
standardised incidence, prevalence, and YLDs attributable 
to TBI, central and eastern Europe also had the highest 
incidence of TBI caused by falls. The second most 
common cause of TBI in most regions was motor vehicle 
road injuries (figure 4A). The main cause of SCI in most 
regions was also falls, which accounted for more than 
50% of age-standardised incidence in nine different GBD 
regions (figure 4). Conflict and terrorism was the most 
common cause in North Africa and the Middle East in 
2016 (figure 4B).
Discussion
This study, in which we used the GBD framework to 
estimate the non-fatal burden of TBI and SCI, is to our 
knowledge the first effort to quantify the burden of these 
conditions at global, regional, and national levels for 
all ages and sexes, and over time, from 1990 to 2016. 
Globally, these conditions cause non-fatal health loss that 
is distributed across various levels of income, geo-
graphies, and the lifespan, and represent a substantial 
proportion of global injury burden that could be averted 
through injury prevention and safety measures.
We identified an increase in global age-standardised 
incidence, prevalence, and YLDs of TBI between 1990 
and 2016. This increase probably reflects the increasing 
rates of falls and road injuries over this period, which 
could in turn be due to increased use of motor vehicles, 
unsafe road conditions, and, in some areas, increased 
rates of alcohol consumption or unsafe infrastructure.22–24 
By contrast, we noted no significant change in the age-
standardised incidence or prevalence of SCI, although 
with global population growth, the absolute number of 
people living with the effects of SCI is expected to 
increase. The increasing global incidence of both TBI 
and SCI starting approximately at age 70 years also shows 
the importance of preventive measures for injuries 
through all years of life—particularly in the context of an 
ageing global population—and of adequate access to 
acute medical care resources such as emergency medical 
services and emergency department care.
Regional patterns differed between TBI and SCI. The 
highest incidence rates of TBI were in central Europe, 
eastern Europe, and central Asia, whereas the high-
est incidence rates of SCI were in high-income North 
Figure 4: Cause composition of age-standardised incidence of traumatic 
brain injury (A) and spinal cord injury (B) by Global Burden of Disease region 
for both sexes, 2016
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America, western Europe, and high-income Asia Pacific. 
Conflict-affected countries in the Middle East—ie, Syria, 
Yemen, and Iraq—and Afghanistan had the highest 
country-specific incidence of SCI, and Syria also had the 
highest incidence of TBI. Rates of TBI and SCI were 
lower in some low SDI countries in regions such as sub-
Saharan Africa, which generally corresponded with the 
geo graphical patterns of falls and road injuries in those 
regions as reported in GBD 2016.3,14,16 These variations in 
the underlying causes of TBI and SCI probably explain 
much of the geographical variation in the incidence of 
TBI and SCI. Access to health-care resources could also 
explain some geographical variation. For example, the 
higher prevalence of SCI in North America and western 
Europe could be related to survival bias in high SDI 
areas, whereby medical services have led to successful 
resuscitation in injury victims who otherwise would have 
died without receiving a TBI or SCI diagnosis code. The 
high rates of TBI in central Europe, eastern Europe, and 
central Asia generally correspond with the high all-injury 
rate estimated in those regions in GBD 2016.3,4,16
Our findings show that, globally, falls and road injuries 
were the most important cause of non-fatal cases of both 
TBI and SCI, reflecting the findings for all 328 diseases 
and injuries from GBD 2016, in which falls were the 
tenth leading cause of age-standardised YLDs from 1990 
to 2016.3 This burden of falls was particularly evident in 
our study for central Europe, eastern Europe, and central 
Asia, where falls were the second most common cause of 
disability in 1990 and the third most common cause in 
2016.3 Although the context in which a fall occurred could 
not be established in this study because of a lack of 
International Classification of Diseases (ICD) coding 
detail, falls can be preventable irrespective of where they 
occur. Falls leading to SCI have been associated with 
alcohol use in countries such as Estonia, so risk factor 
profiles across countries could explain some geographical 
patterns in this study.22 Road injuries were also important 
causes of these conditions, suggesting that achievement 
of Sustainable Development Goal 3.6 (“By 2020, halve the 
number of global deaths and injuries from road traffic 
accidents”) could reduce the burden of conditions such 
as TBI and SCI that can result from road injuries.25
Our estimates for TBI incidence diverged from estim-
ates in other published literature. Our study relied on 
cause-of-injury models that by design estimate the in-
cidence of injuries requiring medical care. A limitation of 
this approach is that some people with TBI, particularly 
mild TBI, might not seek medical attention after injury 
and are thus not captured in the analysis, which could 
lead to underestimation of the global burden of TBI.26,27 
In a study28 done in New Zealand, in which proactive 
screening methods were used to contact people after 
an accident to their upper body (including use of 
broad ICD-10 codes [S00–09] in addition to community-
based case-ascertainment sources to identify individuals 
not seeking medical treatment), the incidence of TBI 
was 790 per 100 000 (substantially higher than that in 
our study), and approximately 30% of people with mild 
TBI did not seek medical attention soon after their 
TBI. However, this study was done in only one country, 
and the findings can probably not be generalised to 
the global population. However, the findings of that 
study28 emphasise the need for other international studies 
to use a comprehensive community-based approach 
for case ascertainment to increase the accuracy of GBD 
estimates.
In general, our study had similar limitations to other 
GBD studies, but with the added complexity and un-
certainty of measuring TBI and SCI within other injury 
estimates, which has not been done previously in the GBD 
framework. In terms of TBI-specific and SCI-specific 
limitations, we used medical record data ex tensively in our 
modelling process, which might not be representative of 
the entire population. This point is pertinent because most 
of the dual-coded clinical data that was used in the 
derivation of cause–nature pro portions was from high-
income countries. Addi tionally, the derivation of the 
incidence coefficient that adjusts for injuries receiving 
outpatient care was based on limited data. These factors 
could have introduced select ion bias, which was addressed 
to some extent by incorporation of income and health-care 
access in our modelling pro cess. However, by relying on 
medical care records, we potentially did not include people 
with mild TBI who did not seek medical care, which 
therefore could be a source of detection bias leading to 
underestimation, although we addressed this issue by 
using cause-of-injury incidence models for all injuries 
requiring medical care, followed by a Dirichlet-based 
modelling approach of cause–nature combinations.26–28 An 
additional limitation stems from the studies examining 
how TBI and SCI can occur together.29 A proportion of 
people can experience an SCI from a traumatic event and 
also experience TBI, and because of the disability-ranking 
approach that we used in our cause–nature proportion 
analysis, these patients would be assigned SCI as their 
nature of injury. Experiencing both SCI and TBI can also 
complicate recovery, and presence of non-brain injuries in 
people with TBI can affect survival,30 although estimates of 
the cumulative effect are outside the scope of this analysis. 
The ICD codes used to identify SCI cases also include 
some injuries that do not necessarily lead to paraplegia or 
tetraplegia, and some such injuries, such as spinal 
cord contusions, can improve over time. Additionally, 
emerging evidence about long-term deficits such as 
dementia, stroke, and increased risk of engagement in 
antisocial behaviour linked to TBI were not included in our 
dis ability computation.31–34 The long-term neurological and 
psychological sequelae of TBI are poorly understood, and 
the epidemiological, neuropathological, and psychi atric 
analyses intended to understand the resultant disabilities 
will be important to incorporate in future assessments. 
Similarly, our analysis does not capture cohort effects over 
time, a limitation that can be addressed in future GBD 
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studies. Overall, the long-term sequelae due to TBI and 
SCI suggest that further work in terms of measurement of 
long-term disability is needed to measure the effect of 
these cond itions more accurately, and to ensure that the 
disability weights accurately re flect the health loss observed 
in clinical practice and experienced by individuals; such 
further work could influence future research into disability-
weight measurement via health loss surveys. The limita-
tions we describe also show how more research is needed, 
particularly in low-income areas of the world, to collect 
comprehensive injury data. Focusing of resources on 
injury epidemiology data could improve the accuracy of 
future epidemiological assessments of TBI and SCI.
In conclusion, the age-standardised incidence, pre-
valence, and YLD of TBI are increasing globally, whereas 
age-standardised rates of SCI have not changed (although 
the number of individuals with SCI is likely to be 
increasing globally). In view of the expense and complexity 
of managing patients with TBI and SCI, ministries of 
health, medical systems, and social support infrastructure 
should focus on development and improvement of injury-
prevention strategies, although maintenance of short-
term and long-term care pathways to mitigate health loss 
and improve outcomes among patients with TBI and SCI 
is also crucial. Finally, measurement of the burden of 
these conditions could be improved with the establishment 
of registry systems for patients with TBI and SCI 
worldwide, which could help to facilitate further research 
and intervention efforts and improve the accuracy of 
future epidemiological assessments of these important 
conditions.
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